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Abstract
Dengue is one of the most rapidly spreading mosquito-borne viral diseases in
the world and inflicts significant health, economic and social burdens on populations.
In this dissertation, I studied different aspects of modeling of dengue and vector-borne
diseases in general. Among various dengue models that have appeared in literature,
some explicitly model the mosquito population, while others model them implicitly.
In spite of extensive use of both modeling approaches, little guidance exists for which
type of model should be preferred. I developed a Bayesian approach that uses a
Markov chain Monte Carlo (MCMC) method to fit disease models to epidemiological
data and used it to explore how well these models explain observed incidence and to
find good estimates for the epidemiological parameters for dengue. I fitted dengue
hemorrhagic fever data from Thailand to both type of models and found using Akaike
Information Criterion that explicitly incorporating the mosquito population may not
be necessary in modeling dengue transmission. On comparing my estimates of the
basic reproduction number, R0 , with other estimates in literature, I found a wide
variability in R0 estimates among studies. This variability in R0 estimate for dengue
transmission is not well understood. By fitting a simple dengue model to dengue
incidence for varying R0 values, I found a logarithmic type relationship between population immunity levels and R0 , which may be a reason for the variability in R0
estimates. The result also highlighted the importance of finding better estimates of
ii

population immunity level to help more accurately estimate R0 and other epidemiological parameters for dengue. Driven by the seasonality in mosquito abundance
and complex dynamics of dengue, introducing a vaccine may induce a transient period immediately after vaccine introduction where prevalence can spike higher than
in the pre-vaccine period. These transient spikes could lead to doubts about the
vaccination program among the public and decision makers, possibly impeding the
vaccination program. Using simple dengue-transmission models, I found that large
transient spikes in prevalence are robust phenomena that occur when vaccine efficacy
and vaccine coverage is not either both very high or both very low. Despite the presence of these spikes, vaccination always reduced total number of infections in the 15
years after vaccine introduction. Therefore, policy makers should prepare for spikes
in prevalence after vaccine introduction to mitigate the burden of these spikes and to
accurately measure the effectiveness of the vaccine program.
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Chapter 1
Introduction
Humankind has always been afflicted by infectious diseases, but epidemics were
comparatively rare before the advent of human civilization. Once people stopped leading a nomadic life and began living in villages, then in towns and cities, pathogens
that cause infectious diseases started spreading easily. People get exposed to these
pathogens either by direct contact (through air, polluted water and food) or by indirect contact (through bloodsucking insect carriers of disease such as mosquitoes, fleas
and lice).
Dengue is one of the most rapidly spreading mosquito-borne viral diseases in
the world. It inflicts significant health, economic and social burden on populations.
Worldwide, an estimated 2.5 billion people live in areas where dengue is an epidemic,
of which approximately 975 million live in urban areas in tropical and sub-tropical
countries in Southeast Asia, the Pacific and the Americas (Figure 1.1). Dengue
has been recognized in over 100 countries and an estimated 50–100 million dengue
infections occur annually (Guzmán and Kouri, 2002). Moreover, the global estimated
number of disability-adjusted life years (DALYs) lost to dengue in 2001 was 528, 000.
Dengue virus (DEN) is a small, spherical and single-stranded RNA virus in
1

Figure 1.1: Areas at risk for dengue transmission, 2008 (WHO, 2009).

the genus Flavivirus in the family Flaviviridae, which also includes yellow fever virus
and West Nile Virus. Dengue viruses are divided into four distinct classes, known
as serotypes, referred to as DEN-1, DEN-2, DEN-3 and DEN-4. Infection with one
serotype provides immunity to other viruses in that same serotype, but no long-term
immunity to the other serotypes. Within each serotype, distinct genotypes have
been identified which indicates the extensive genetic variability within the dengue
serotypes. An individual infected with one of the four serotypes such that the individual have had no prior infection with any of the serotype is said to be infected
with primary infection. Similarly, an infected individual is said to be infected with
secondary infection if the individual have had prior infection with any one of the
dengue serotypes. Persons living in areas where dengue is an endemic can be infected
with three and probably four dengue serotypes during their lifetime (Gubler, 1998a).
The various serotypes of the dengue virus are transmitted to humans through
the bites of Aedes mosquitoes. Aedes aegypti mosquitoes are the predominant vectors
for dengue infection, however Aedes albopictus and other Aedes species are also able
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to transmit dengue with varying degree of efficiency. The mosquitoes acquire the
virus when they bite an infected human. The mosquitoes are capable of transmitting
dengue if they bite another human immediately or after incubating the infection
for eight to twelve days, which is known as the extrinsic incubation period. The
mosquitoes remain infected for rest of their lives. Vertical transmission of virus from
mother to offspring is thought to be rare in both mosquitoes and humans (Gubler,
1998b; Guzmán and Kouri, 2002; Sabin, 1952; Siler et al., 1926).
Once the dengue virus is inoculated into a human host, it incubates for a period of 4–10 days, the intrinsic incubation period. Following incubation, an infected
person enters the acute phase of infection for about 5 days. The host recovers from
the infection usually within 7–10 days. Infection with one type of dengue serotype
provides lifelong protective immunity to the infecting serotype, and possibly partial
short-lived protection from infection with other dengue serotypes (Sabin, 1952). The
symptoms of disease vary greatly: mild fever, high fever with severe headache and
joint pain, and internal hemorrhaging, circulatory failure and death. The cases are
classified in order of increasing severity as dengue fever (DF), dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS) (Guzmán and Kouri, 2002; Halstead,
2007). The severity of disease in an individual is determined by several factors such
as age, ethnicity, previous dengue infection and possibly the presence of some chronic
diseases (Guzmán and Kouri, 2002). Young children can be especially susceptible to
dengue morbidity (Guzmán et al., 2002). Most patients who develop severe forms of
dengue (DHF or DSS) have had prior infections with one or more dengue serotypes
(Halstead, 2007). One explanation for this phenomenon is antibody-dependent enhancement (ADE), where the presence of antibodies to one dengue serotype enhance
the replication of viruses from other serotypes, perhaps leading to increased susceptibility to infection or transmission once infected, in addition to increasing the risk
3

of severe disease (Halstead, 2007). Certain dengue genotypes, particularly those of
DEN-2, are thought to be more virulent than others, since more number of cases of
DHF have been associated with DEN-2 than with the other serotypes (Rico-Hesse,
2003).
Numerous approaches have been used to understand the epidemiology of dengue
fever (DF) and dengue hemorrhagic fever (DHF). There are several ecological characteristics of the dengue virus (DENV) that have often been explored using mathematical models. Various mathematical models for dengue infection have appeared so
far, and successfully helped us understand the different aspects of the disease. For
example, a series of studies by Focks et al. (1993a,b, 1995, 2000) investigated the
quantitative value of models using epidemiological data and simulations, while others
focused purely on qualitative patterns motivated by ecological interests (Esteva and
Mo Yang, 2005; Esteva and Vargas, 2000b; Ferguson et al., 1999a).
To ensure that a mathematical model captures the essential features of epidemics, it is imperative to validate the model by fitting it to observed data. Several
estimation methods have been used in the literature to estimate parameters. Leastsquares error fitting has been widely used for vector–host models (Chowell et al.,
2007; Mubayi et al., 2010) and recently the expectation maximization (EM) algorithm has seen some use (Duncan and Gyöngy, 2006; Lavielle et al., 2011). In this
dissertation, I present and use a Bayesian Markov chain Monte Carlo (MCMC) technique for estimation as it provides a huge amount of modeling flexibility. Compared
with other estimation methods, Bayesian MCMC technique has advantage of giving
a complete posterior distribution for parameters as posterior distributions that enables easy analysis of model parameters or function of parameters. Moreover being a
procedure-based approach, it is easy to implement.
Among various models that have been used to study dengue transmission, some
4

explicitly model the mosquito population (e.g. Esteva and Vargas, 2000a; Medlock
et al., 2009; Wearing and Rohani, 2006), while others model the mosquitoes implicitly
in the transmission term (e.g. Adams et al., 2006; Cummings et al., 2005; Nagao and
Koelle, 2008). In spite of extensive use of both modeling approaches, little guidance
exists for which type of model should be preferred. In particular, I found no comparison in the literature of how well these models explain observed incidence. I studied
the impact of these modeling assumptions on the dynamics of dengue to fit dengue
hemorrhagic fever (DHF) data from Thailand to simple dengue models with and
without explicitly modeling mosquitoes using Bayesian MCMC estimation. I found
the parameter estimates obtained from both models consistent with previous studies.
Most importantly, model selection found that the model with implicit mosquitoes was
substantially better than the model with explicit mosquitoes for the DHF data from
Thailand. Therefore, explicitly incorporating the mosquito population may not be
necessary in modeling dengue transmission.
In mathematical modeling of diseases, the basic reproduction number (R0 )
that is total number of secondary cases generated by one case during its infectious
period in a completely susceptible population is an important measure as it provides a
threshold to determine the amount of effort that is necessary to prevent an epidemic or
to eliminate a disease from a population. The basic reproduction number for dengue
transmission in Thailand has been estimated by various studies (e.g. Adams et al.,
2006; Chao et al., 2012; Cummings et al., 2009; Nagao and Koelle, 2008). However;
estimates of R0 for dengue transmission vary considerably between these studies.
These R0 estimates vary from low values of around 1–3 to higher values of 10–12.
The estimates of R0 from my study of estimating parameters using Bayesian MCMC
were in the range of 1–3. This variability in the estimates of R0 is not well understood.
Inaccurate estimates of R0 may lead to incorrect assessment of disease risk and so it
5

is important to investigate this variability in R0 estimates among studies. In order
to understand the likely reasons for this variability, we fitted a simple dengue model
to dengue incidence for varying values of reproduction number R0 and found that
different levels of population immunity may lead to wide variations in estimates of
the basic reproduction number. More specifically, there seems to be logarithmic type
relationship between the level of population immunity and the basic reproduction
number, so estimating the level of population immunity and the basic reproduction
number together may not provide accurate model parameters. Thus in order to fit
dengue models to observed data from Thailand, it may be necessary to use appropriate
estimates for the proportion of the population immune to infection at the beginning
of the epidemic.
With the expanding geographic distribution and increased disease incidence
in past several decades, the prevention and control of dengue infection has become
very important. Unfortunately, tools available to prevent dengue infection are very
limited. For many years, some viral diseases have been controlled using vaccines,
however a dengue vaccine is not yet available. Therefore, in order to reduce or prevent
dengue virus transmission, there is currently no alternative to vector control. The
dengue vector control programs in most endemic countries have been frequently found
insufficient, ineffective or both. The low success rate of vector control, the continuing
spread of dengue and the increasing incidence of dengue call for a safe, effective and
affordable vaccine. The ideal dengue vaccine should be affordable, free of side effects,
and should induce life-long protection against infection with any of the four dengue
serotypes (i.e. tetravalent) (Guzmán et al., 2010).
Recently, significant progress has been made in the development of vaccine
candidates and several vaccine candidates are showing promise in clinical studies
(Coller and Clements, 2011). A vaccine candidate from Sanofi Pasteur showed effi6

cacy of 30% and protection against 3 of the 4 serotypes of dengue (Halstead, 2012).
It is expected that a licensed vaccine for dengue will be available in less than 10 years
(Guzmán et al., 2010). Once vaccine is available, policy makers will need to develop
suitable policies to allocate the vaccine. Mathematical models of dengue transmission
predict complex temporal patterns in prevalence, driven by seasonal oscillations in
mosquito abundance. In particular, vaccine introduction may induce a transient period immediately after vaccine introduction where prevalence can spike higher than
in the pre-vaccine period. These spikes in prevalence could lead to doubts about
the vaccination program among the public and even among decision makers, possibly impeding the vaccination program. Using simple dengue-transmission models,
I found that large transient spikes in prevalence are robust phenomena that occur
when vaccine coverage and vaccine efficacy are not either both very high or both very
low. Despite the presence of transient spikes in prevalence, the models predict that
vaccination does always reduce the total number of infections in the 15 years after
vaccine introduction. I concluded that policy makers should prepare for spikes in
prevalence after vaccine introduction to mitigate the burden of these spikes and to
accurately measure the effectiveness of the vaccine program.
The chapters hereafter are organized as follows: In chapter 2, I present the
Bayesian MCMC approach to estimate parameters of deterministic mathematical
models. Using artificial incidence data, I show that the method can accurately estimate the parameter values in epidemic models. In chapter 3, I apply the Bayesian
MCMC approach to vector–host and SIR-type models of dengue to estimate parameters using monthly DHF-case data from Thailand and perform model selection to
chose a model that fits observed data more parsimoniously. In chapter 4, the variability in the estimates of the basic reproduction number for dengue transmission in
Thailand is investigated using observed data from Thailand. The short- and long7

term impacts of vaccine introduction and in particular, possibility of large spikes in
prevalence immediately after introduction of dengue vaccine is analyzed in chapter 5.
Finally, I discuss general conclusions in chapter 6.
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Chapter 2
Parameter estimation using
Bayeisan MCMC
One of the main goals of the mathematical modeling of infectious diseases is
to make reasonable predictions and develop control measures like vaccination and
isolation. In order to achieve these goals, it is imperative that the corresponding
mathematical model captures the essential features of the course of the disease outbreak. Thus, estimating unknown parameters of the models and their validation by
checking whether they fit the observed data becomes very important. It is challenging
to resolve this problem for a system of differential equations, which are the typical
form for infectious disease models. Generally, there are no closed-form solutions and
there are many unknown parameters. In addition, direct data on individual-level
parameters such as transmission or susceptibility are extremely limited, due to an inability to feasibly conduct infection experiments, and instead must be estimated from
indirect population-level data. Most studies either use point estimates of parameter
values derived from clinical and laboratory experiments or from population-level data.
There are several methods that have been used to estimate the parameters of
9

mathematical models. The method that has been widely used for vector-borne disease
models is least-squares error fitting techniques. Least-squares fitting minimizes the
sum of squared residuals, a residual being the difference between an observed value
and the fitted value provided by the model. Chowell et al. (2007) used least-squares
error techniques as one of the methods to estimate the transmissibility of dengue fever
during a 2002 epidemic in the Mexican state of Colima, using municipal epidemic data
to evaluate the effect of spatial heterogeneity. Mubayi et al. (2010) computed initial
estimates of parameters for Kala-azar (leishmaniasis) using least-squares fitting and
monthly reported data from Indian state of Bihar for the years 2002 and 2005. They
used these parameter estimates to compute, Kala-azar’s reproduction numbers for
the 21 most affected districts of Bihar and analyzed the impact of underreporting.
Recently, the expectation maximization (EM) algorithm has been used to estimate unknown parameters of disease models. The EM algorithm is an iterative
scheme for obtaining maximum likelihood estimates. Duncan and Gyöngy (2006)
used the EM algorithm to estimate the parameters of an age-structured model of
smallpox and estimated R0 using data from smallpox deaths in London over the
period of 1708 to 1748. A variant of the EM algorithm, stochastic approximation expectation maximization was used by Lavielle et al. (2011) to estimate the parameters
of a long-term HIV dynamic model.
A more sophisticated method to find good estimates for the unknown parameters of a model is to take a Bayesian approach that uses Markov chain Monte Carlo
(MCMC) simulations to estimate the unknown parameters. In the Bayesian approach
the parameter of interest is considered to be a quantity whose variation can be described by a probability distribution. Initially, this is a subjective distribution called
the prior distribution, based on the experimenter’s belief, which is formulated before
the data are seen. A sample is then taken from a population indexed by the param10

eter of interest and the prior distribution is transformed using Bayes’s Theorem into
the posterior distribution.
Simple models allow the posterior distribution to be calculated explicitly, while
other methods must be used for complex models. MCMC methods are a class of algorithms for sampling from probability distributions based on constructing a Markov
chain with the desired stationary distribution. In Bayesian models, the MCMC
method estimates the posterior probability distribution of parameters (Gelman and
Rubin, 1996).
MCMC methods are used widely in many different areas of research and
many disease modelers have used it to estimate the parameters of epidemic models. Cauchemez et al. (2004) used the Bayesian MCMC method on longitudinal data
in order to estimate the main characteristics of infuenza transmission in households.
Huang et al. (2006) used a hierarchical Bayesian approach to implement MCMC simulations to estimate the dynamic parameters of a HIV model proposed for characterizing long-term viral dynamics with antiretroviral therapy using longitudinal clinical
data. Brownstein et al. (2004) estimated the parameters of human and nonhuman
surveillance models for West Nile Virus using MCMC simulations and demonstrated
that mosquito surveillance was a more accurate predictor of human risk than monitoring dead and infected wild birds for West Nile Virus. A Bayesian analysis of a
dynamic model for the spread of the Usutu virus by MCMC improved the model fit
and revealed the structure of interdependencies between model parameters (Reiczigel
et al., 2010).
One of the reasons that makes Bayesian MCMC an attractive choice is that
it is generally straightforward to implement and provides a huge amount of modeling
flexibility. The method enables analysis of all of the model parameters and functions
of the parameters. It also has advantage of not giving point estimates of parameters
11

but distributions for the parameters that capture uncertainty. Moreover, posterior
summaries such as means, medians, maxima, minima, credible intervals, etc., can
be easily obtained for individual parameters or for joint distributions of parameters.
Also, if the data available is limited it reflects in the result by giving wider posterior
distributions for the parameters.

2.1

Baysian Markov chain Monte Carlo estimation
The method begins with a mathematical model of disease and appropriate

epidemiological data available for the disease. Bayesian inference is then performed,
in which the information regarding the parameters of the model from previous studies
is regarded as prior knowledge and is combined with the epidemiological data to
update the information about the unknown parameters of the model. The Markov
chain Monte Carlo method is used to update the parameter distributions.
Given a set of differential equations with parameters θ and the epidemiological
data Di = D(ti ) at the discrete time points {t1 , t2 , ....}, the aim is to find a set of free
parameters so that the model fits the data at those time points. Let y(ti | θ) be the
time series produced by the mathematical model at the same discrete time point, ti ’s
for which the data is available. An error function is assigned to this data and aim
is to minimize the error. The most common error function is the mean square error,
which can be written as:

2

E =

X

2
Di − y(ti | θ)

(2.1)

i

Next, a likelihood function for the parameters of the model is constructed. The likelihood is the conditional probability of obtaining the data given the set of parameter
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values. The likelihood function is derived by assigning some probability distribution
to the error function. There are several ways to form the likelihood function, for
example assigning the error function to have a binomial, normal or Poisson distribution. But in practice, a normal distribution works well, so we assumed that the error
function (2.1) obeys a normal distribution with zero mean and standard deviation 1
and write likelihood function as

L(θ) = Pr(D | θ) = exp(−E 2 )

(2.2)

In order to use Bayesian inference to estimate the parameters, a prior distribution for all the parameters is needed. If we have some prior information about the
parameters, then it can be used to assign the prior distribution to the parameters.
However, if we do not know any specific, definite information which can be used to
assign the prior distribution to the parameters, then we can choose a prior which is
flat. In this case the prior is called a noninformative prior. A noninformative prior expresses vague or general information about the parameters such as “the parameter is
positive” or “the parameter is less than some limit”. We called the prior distribution
for the parameters Pr(θ).
Finally, the posterior distribution of the unknown parameters is calculated.
The posterior distribution is the conditional distribution of the parameter values
given the data. By Bayes’s Theorem,

Pr(θ | D) =

Pr(D | θ) Pr(θ)
,
Pr(D)

(2.3)

where P (D | θ) is the likelihood function L(θ) from (2.2), Pr(θ | D) is the posterior
distribution, Pr(θ) is the prior distribution and Pr(D) is called the evidence, which
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is an integral of the likelihood over the prior distribution of the parameters:
Z
Pr(D) =

Pr(D | θ) Pr(θ) dθ.

(2.4)

The posterior distribution can be estimated by calculating the expression (2.3). Unfortunately, Pr(D) is computationally difficult if not impossible to calculate for all
but the simplest likelihood as there is not enough information and there are two many
possible parameter values.
However, we do know that the posterior distribution is proportional to the
likelihood times the prior:

Pr(θ | D) ∝ Pr(D | θ) Pr(θ).

(2.5)

Using Bayes’s Theorem (2.5), a Markov chain is formed which asymptotically converges to the posterior distribution by using a simple Metropolis Algorithm. The
Metropolis Algorithm is an iterative procedure that uses an acceptance–rejection rule
to converge to the required distribution (Gelman et al., 2004). The algorithm is:
1. Start with some initial guess for the parameter values. A starting point θ0 is
chosen randomly from the prior distribution Pr(θ).
2. For each iteration n = 1, 2, 3, ......
(a) A new proposed set of parameter values is generated by sampling θ∗
from the proposal distribution J (θ∗ | θn−1 ). The proposal distribution
J (θ∗ | θn−1 ) must be symmetric, i.e. J (θ∗ | θn−1 ) = J (θn−1 | θ∗ ), for this
algorithm.
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(b) Using the likelihood function, the ratio of the posterior estimates

r = min


Pr(θ∗ | D) Pr(θ∗ )
,1
Pr(θn−1 | D) Pr(θn−1 )

(2.6)

is calculated.
(c) A random uniform number (α) between 0 and 1 is generated. Then the
parameter values for this iteration are

θn =




θ ∗

if α < r,



θn−1

otherwise.

(2.7)

This algorithm must be run for enough iterations for the parameter values
to converge to the posterior distribution. There are several convergence diagnostics
that can be employed to detect whether the chain has converged (Cowles and Carlin,
1996). We used the Gelman–Rubin test (Gelman and Rubin, 1992) for the convergence diagnostic of our simulations, which is based on multiple independent simulated
chains. The variances within each chain are compared to the variances between the
chains: large deviation between these two variances indicates non-convergence.
The posterior is insensitive to the choice of proposal density, J(θ∗ | θn−1 ), but
the number of iterations until the chain converges may be heavily affected. It is difficult to choose an efficient proposal distribution, but normal distributions have been
found to be useful in many problems (Gelman et al., 2004). We used a multivariate
normal distribution with mean θn−1 and covariance λ2 Σ as our proposal distribution,



J θ∗ | θn−1 ∼ N θn−1 , λ2 Σ .

(2.8)

For the multivariate normal proposal distribution, for optimal convergence, proposals
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should be accepted at a rate of 0.44 in one dimension and 0.23 in higher dimensions
(Gelman et al., 2004). To achieve this, we used a variant of the Metropolis Algorithm
that updates the covariance matrix Σ and the scaling factor λ of the proposal distribution after every 500 iterations. We initially chose the covariance to be the d × d
√
identity matrix (Σ0 = I) and the initial scaling factor to be λ0 = 2.4/ d, where d is
the number of parameters being estimated. After every 500 iterations, the covariance
matrix was updated by
Σk = pΣk−1 + (1 − p)Σ ∗

(2.9)

where Σ ∗ is the covariance of the last 500 parameter values and p = 0.25 is the weight
given to the old covariance matrix. Similarly, the scaling factor was updated using
the Robbins–Monro algorithm (Robbins and Monro, 1951),

λk = λk−1 exp

α∗ − α̂
k


,

(2.10)

where α∗ is the acceptance rate for the last 500 iterations and the target acceptance
rate is
α̂ =




0.44 for d = 1,

(2.11)



0.23 for d > 1.
The adaptive algorithm we used has two phases: first, the adaptive phase,
which was run until the Gelman–Rubin convergence test passed, and then the fixed
phase, where one of chains was chosen randomly and using its last estimates of the
parameters along with the updated covariance matrix and scaling factor as starting
point, the algorithm was run for next m iterations to sample from the posterior
distribution without updating the covariance matrix and the scaling factor. We used
the samples from the only last phase for the final inferences.
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2.2

Examples
We provide two simple examples of parameter estimation of a simple SIR

model using Bayesian MCMC. To show that the method works, we used synthetic
data generated for some particular choice of parameter values and compared the
estimates from Bayesian MCMC with these values.
A simple SIR model is given by
dS
= −βIS,
dt
dI
= βIS − γI,
dt
dR
= γI,
dt

(2.12)

where β is contact rate and γ is recovery rate and S, I and R are numbers of susceptibles, infectious and recovered in the population (Anderson and May, 1992) In our
first example we estimated the contact rate and recovery rate of this SIR model using
the synthetic data. The initial conditions of the model were also estimated along with
the parameters in the second example.

2.2.1

Estimating contact rate and recovery rate
We estimated the contact rate β and the recovery rate γ in the aforementioned

SIR model. In general, the epidemiological data is available as the number of infectious individuals at different points in time, so we generated a synthetic data set for
the number of infectious individuals by solving the SIR model using particular values
of parameters β and γ. We chose β = 0.5 per person per day, γ = 0.3333 per day
and initial conditions (S(0), I(0), R(0)) = (1, 0.000001, 0) to generate the synthetic
data for infectious individuals at 180 daily data points using the ODE solver ODE45

17

Parameter True Value Initial guesses
β
0.5
0.8, 0.4, 0.6, 0.5
γ
0.3333
0.2, 0.6, 0.4, 0.5
Table 2.1: Initial guesses used to estimate β and γ

in Matlab. Now we used our Bayesian MCMC algorithm to estimate the values of
contact rate β and recovery rate γ. At each step of our simulations, we generated the
simulation data for infectious individuals at the same data points for which we have
obtained the synthetic data using same initial conditions and the current estimates
of parameter values to form the error function. Following the steps of the method
described in section 2.1, the error function (2.1)) was formed . Assuming lack of any
prior information about the parameters we wished to estimate, we chose noninformative priors for β and γ. We specified uniform distributions (U (0, 10)) for both the
parameters. Table 2.1 provides the parameter values used to generate synthetic data
as well as initial guesses used for parameter values to begin the simulations.
We ran four parallel MCMC chains and used Gelman–Rubin test along with
an upper bound of 5000 iterations for stopping criteria. Once the convergence criteria
was met, the estimates of parameters for each MCMC chain against the number of
iteration was plotted (Figure 2.1).
All chains converged to distributions around the true values of the parameters.
Finally, to make inferences about our result, second phase of the adaptive algorithm
was run for next 1000 iterations (Figure 2.2). We used the posterior density to
summarize our output in terms of means, medians and credible intervals (Table 2.2).
The mean and median estimates were very close to the true values (0.5000, 0.3333),
with the mean being slightly closer than the median in this example. The credible
intervals included the true parameter values and were relatively narrow, suggesting
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Figure 2.1: Estimates of β and γ vs. number of iterations.
Parameter True Value Mean
β
0.5
0.5002
γ
0.3333
0.3333

Median
0.5003
0.3338

90% Credible Interval
(0.4897, 0.5110)
(0.3201, 0.3464)

Table 2.2: Posterior summary of β and γ. See also Figure 2.2.

the data was sufficient for good estimation of the parameters.

2.2.2

Estimating initial conditions along with parameters
In general, we do not know the initial conditions that should be used for solving

the mathematical models, so we must also estimate the initial conditions as well. Here
we estimated the initial conditions for the SIR model along with the contact rate β
and the recovery rate γ. The three equations in our SIR model resulted into three
initial conditions, that is, one for each initial number of susceptibles S(0), initial
number of infectious I(0) and initial number of recovered R(0). In the beginning of
the epidemic, we assumed that the number of recovered R(0) must be 0, so is not
needed to be estimated. We followed the same steps as before to estimate β, γ, S(0)
and I(0) in order to fit the synthetic data generated in the previous example to the
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Figure 2.2: Histogram for posterior densities of parameters β and γ. See also Table 2.2.
Parameter
β
µ
S0
I0

True Value
0.5
0.3333
1
0.000001

Initial guesses
0.8, 0.4, 0.6, 0.5
0.2, 0.6, 0.4, 0.5
0.3, 0.7, 0.4, 0
0.00000124, 0.00000226, 0.000000083, 0.000000152

Table 2.3: Initial guesses used to estimate β, γ, S(0) and I(0)

model. We began with over-dispersed initial guesses (Table 2.3) and assigned uniform
priors to the parameters and initial conditions.
We ran four parallel MCMC chains and used Gelman–Rubin test along with an
upper bound of 20, 000 iterations for stopping criteria. Once the convergence criteria
was met, the estimates of parameters and initial conditions for each MCMC chain
was plotted (Figure 2.3). The second phase of the adaptive algorithm was run for
next 2000 iterations to make inferences about the results. The posterior density was
used to summarize the output (Figure 2.3) in terms of means, medians and credible
intervals (Table 2.4).
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Figure 2.3: Estimates of β, γ, S(0) and I(0) vs. number of iterations

Parameter
β
γ
S0
I0

True Value
0.5
0.3333
1
0.000001

Mean
Median
0.5334
0.5240
0.3260
0.3242
0.9297
0.9363
0.00000118 0.00000121

90% Credible Interval
(0.4373, 0.6502)
(0.2714, 0.4019)
(0.6970, , 1.2940)
(0.00000081, 0.00000162)

Table 2.4: Posterior summary of β, γ, S(0) and I(0). See also Figure 2.4.
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Figure 2.4: Histogram for posterior densities of β, γ, S(0) and I(0). See also Table 2.4
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The mean and median estimates for the parameters β and γ were close to
their true values. The mean for β was slightly closer to its true value than the
median, whereas the median was slightly closer to the true value of γ than the mean.
The mean and median estimates for the initial conditions were very close to the
true values (1, 0.000001). All the credible intervals included the true values, but the
credible intervals of parameters were wider compared to the ones obtained when only
parameters were estimated.

2.3

Summary
We developed and presented a method of Bayesian MCMC estimation for

fitting disease models to observed data. In this method, prior information from previous studies regarding the model parameters is combined with epidemiological data
to update the information about the model parameters. The connection between the
observed data and the parameters is made by a likelihood function. The prior distribution of model parameters are then transformed in the posterior distribution by
Bayes’s Theorem. In Bayesian models, slight deviations from simple models renders
the models intractable analytically. So, we used a MCMC method based on Metropolis algorithm to generate posterior distribution for the model parameters. To improve
the speed of convergence to the posterior distribution, a variant of Metropolis algorithm that updates the covariance matrix and scaling factor of jumping distribution
after every fixed number of iterations was used. In our simulations, Gelman–Rubin
test determined when the convergence was met and was used as stopping criteria.
We demonstrated the use of the Bayesian MCMC estimation by applying it
on a simple SIR-type model. We generated artificial incidence data by running the
model with fixed parameter values and initial conditions. We performed Bayesian
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MCMC estimation on the model and the artificial data to find estimates for the model
parameters and initial conditions. The mean and median estimates for the parameters
and initial conditions were very accurate and the credible intervals captured the
uncertainties in the estimates well.
Parameter estimation using epidemiological data is one of the key aspects of
disease modeling. We showed that Bayesian MCMC estimation is a novel method
to estimate parameters of disease models and differential equation models in general.
The method is easy to implement and has advantage of giving complete posterior
distribution for parameters that enables easy analysis of model parameters or function
of parameters.
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Chapter 3
Comparing vector–host and SIR
models for dengue transmission
3.1

Introduction
Dengue infection is one of the leading causes of illness in the tropics and

subtropics, where it inflicts substantial health, economic and social burdens (Center
for Disease Control and Prevention, Accessed January 14, 2013). Humans are infected
with dengue viruses by the bite of an infective female mosquito Aedes aegypti, the
principal vector of dengue. Once a person gets bitten by an infective mosquito, the
virus undergoes an incubation period of about 4 to 7 days, after which the person
enters the acute phase of infection. The acute phase can be as short as 2 days and
as long as 10 days. If other female A. aegypti mosquitoes bite the ill person during
this acute phase, those mosquitoes may become infected and subsequently begin the
transmission cycle anew. Dengue infection is generally characterized by a sudden
onset of fever and other nonspecific signs and symptoms, including frontal headache,
body aches, nausea and vomiting (Gubler, 1998a). Symptoms range from mild fever
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to high fever with severe headache and joint pain, and even to internal hemorrhaging,
circulatory failure and death. Cases are classified, in order of increasing severity as
dengue fever, dengue hemorrhagic fever (DHF) and dengue shock syndrome (Medlock
et al., 2009). Dengue has been recognized in over 100 countries and an estimated 50–
100 million cases of dengue fever and several hundred thousand DHF cases occur
yearly, depending on epidemic activity (Guzmán and Kouri, 2002). Particularly, in
Thailand, dengue disease incidence has increased from 9 per 100 000 in 1958 to 189
per 100 000 in 1998, with the largest reported incidence of 325 per 100 000 in 1987,
making dengue a severe public health problem in Thailand (Nisalak et al., 2003).
Several mathematical models have been proposed to investigate dengue epidemiology, some of which explicitly model the mosquito population (e.g. Esteva and
Vargas, 2000a; Medlock et al., 2009; Wearing and Rohani, 2006), while others implicitly model it in the transmission term (e.g. Adams et al., 2006; Cummings et al.,
2005; Nagao and Koelle, 2008). Although both kinds of models have been extensively
used for dengue, little guidance exists for which type of model should be preferred. In
particular, there has been no comparison of how well these models explain observed
incidence. In this study, we considered simple dengue models with and without explicitly modeling mosquitoes, fit both models to DHF incidence data, and used model
selection to compare the models.
Fitting models to data validates the model as well as provides estimates of
unknown model parameters. There are some examples in the literature where dengue
models have been fit to data. Chowell et al. (Chowell et al., 2007) estimated the
transmissibility of dengue during a 2002 epidemic in the Mexican state of Colima
using municipal epidemic data to evaluate the effect of spatial heterogeneity. Ferguson
et al. (Ferguson et al., 1999b) used longitudinal incidence of serious dengue disease
from Thailand and estimated the basic reproductive number R0 to gain insight into
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the transmission dynamics and epidemiology of dengue. We fit a simple vector–host
dengue model as well as an SIR-type dengue model and obtain estimates of unknown
parameters like recovery rate, probability of severe form of disease, mosquito mortality
rate, etc.
The goal of the present study is to understand the impact of some modeling
assumptions on quantifying estimates of epidemiological metrics for dengue. We
applied Bayesian Markov chain Monte Carlo (MCMC) estimation on a simple vector–
host dengue model as well as an SIR-type dengue model to estimate model parameters
using monthly DHF incidence data in Thailand for January 1984 to March 1985.
The Bayesian MCMC techniques that we used in this study have been commonly
used to estimate model parameters of infectious diseases (Brownstein et al., 2004;
Cauchemez et al., 2004; Huang et al., 2006; Reiczigel et al., 2010). We use the
posterior distribution of the model parameters obtained from Bayesian MCMC to
perform uncertainty and sensitivity analysis of basic reproductive number R0 and
thereafter, use model selection on a set of vector–host and SIR models to find a
model which agrees with the data most parsimoniously.

3.2

Methods
We built two mathematical models of dengue transmission, one in which the

mosquitoes are explicitly tracked and another without explicit mosquito populations.
We then used Bayesian MCMC to fit DHF data from Thailand to these two models.
In this section, we outline the data source, models and methods and refer to more
detailed descriptions in Appendix A.
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Figure 3.1: Monthly dengue hemorrhagic fever (DHF) incidence in Thailand from
1983 to 1997.

3.2.1

Data Source
The Thailand Ministry of Public Health have been recording the number of

DHF cases since 1972. Cases are diagnosed using criteria established by the World
Health Organization. We obtained the monthly incidence of DHF for Thailand from
1983 to 1997 (Figure 3.1) (Johns Hopkins Center for Immunization Research, Accessed January 14, 2013). We chose one epidemic, from January 1984 to March 1985
(Figure 3.2), to fit the dengue models: this particular epidemic was chosen as a clear,
representative example among this data. More specifically, we used the cumulative
monthly number of DHF cases for the period January 1984 to March 1985. Cumulative incidence is generally smoother than the original incidence data and thus easier
to fit and it also easily handles delayed reporting on holidays and weekends.

3.2.2

Vector–host model
The Ross–Macdonald model, originally developed for malaria, is a standard

mathematical model for vector-borne pathogens that tracks infections in both humans
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Figure 3.2: Monthly DHF incidence in Thailand from January 1984 to March 1985.

and mosquitoes (Macdonald, 1957). Following this framework, we built a vector–host
model for dengue consisting of three human host compartments, susceptible (the
number of susceptible humans is HS ), infectious (HI ) and recovered (HR ), and two
mosquito compartments, susceptible (VS ) and infectious (VI ). Mosquitoes do not
recover from infection. The model is the system of differential equations
dHS
dt
dHI
dt
dHR
dt
dVS
dt
dVI
dt

= BH − mcβH
= mcβH

VI
HS − µH HS ,
V

VI
HS − γH HI − µH HI ,
V

= γH HI − µH HR ,
= BV − cβV
= cβV

(3.1)

HI
VS − µV VS ,
H

HI
VS − µV VI ,
H

where H = HS + HI + HR and V = VS + VI are the human and mosquito population
sizes, respectively. A susceptible human gets infected with force of infection mcβH VVI ,
where m is number of mosquitoes per person, c is mean rate of bites per mosquito
and βH is the mosquito-to-human transmission probability per bite. Infectious people
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recover at rate γH . The force of infection for mosquitoes is cβV HHI , where βV is
the human-to-mosquito transmission probability. For simplicity, we ignored diseaseinduced mortality in both humans and mosquitoes, which is small (Burattini et al.,
2008). Because we only fit the model to an epidemic lasting about a year, we assumed
the human population was constant size by using the birth rate BH = µH H. We also
assumed the mosquito population was constant size (BV = µV V ), neglecting seasonal
fluctuations for simplicity.
Standard mathematical analysis of the model (Appendix A.1) shows that the
basic reproductive number, the number of new human infections caused by a single
infected human in an otherwise completely susceptible population, is

R0 =

mc2 βH βV
.
µV (µH + γH )

(3.2)

In addition, there are two equilibrium points, the disease-free equilibrium and the
endemic equilibrium. An equilibrium point is asymptotically stable if nearby orbits
converge to it as time increases, and it is globally asymptotically stable if all orbits,
not just those nearby, converge to the equilibrium (Alligood et al., 1996). For R0 >
1, the disease-free equilibrium is unstable and the endemic equilibrium is locally
asymptotically stable. The disease-free equilibrium is globally asymptotically stable
when R0 ≤ 1 (and the endemic equilibrium is out of the relevant state space, having
HI and VI negative, and unstable).
To simplify the parameter estimation, rather than fitting human mortality
rate along with the other parameters, we fixed µH = 1/69 y−1 based on the average
human duration of life in Thailand in 1984 of about 69 years (World Bank, Accessed
January 14, 2013). The remaining unknown parameters are the human recovery rate
(γH ), the mosquito mortality rate (µV ), the probability of DHF (p), the mosquito
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biting rate (c), the number of mosquitoes per person (m), the mosquito-to-human
transmission probability (βH ) and the human-to-mosquito transmission probability
(βV ). The biting rate, c, always appears in the model multiplied with either βH or
βV . Similarly, m always appears multiplied with βH . Therefore, only 2 of these 4
parameters can be separately estimated, which we chose to be βaH = mcβH and
βaV = cβV . In addition, the initial proportion of humans recovered in the host
population (hR (0) = HR (0)/H) as well as initial proportion of mosquitoes infected in
the vector population (vI (0) = VI (0)/V ) are unknown and must be determined. Thus,
we estimated a total of 5 unknown parameters and 2 initial conditions for the vector–
host model. We used the incidence data for January 1984 and Thailand’s population
in year 1984 to calculate initial conditions for initial proportion of hosts infected,
i.e. hI (0) = HI (0)/H(0), where HI (0) = 454 and H(0) = 46 806 000. Since both
the human and mosquito populations are constant, initial proportions of susceptible
humans and mosquitoes were calculated using the other initial conditions, i.e. hS (0) =
1 − hI (0) − hR (0) and vS (0) = 1 − vI (0).

3.2.3

SIR model
Dengue transmission has been extensively modeled using SIR-type models,

which only explicitly track human infections (e.g. Adams et al., 2006; Cummings
et al., 2005; Nagao and Koelle, 2008). These SIR models are simpler than vector–
host models, making analysis and parameter estimation easier. SIR models for dengue
have typically been constructed directly (e.g. Cummings et al., 2005). Alternately,
an SIR model can be derived from a vector–host model by assuming that infection
dynamics in the vector are fast compared to those of the host, a quasi-equilibrium
approximation (Keeling and Rohani, 2011).
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We used a standard SIR model,
dHS
HI
= BH − β HS − µH HS ,
dt
H
dHI
HI
= β HS − γH HI − µH HI ,
dt
H
dHR
= γH HI − µH HR ,
dt

(3.3)

where H = HS + HI + HR is the human population size. Again, we kept the population size constant by setting the birth rate to BH = µH H. A susceptible person gets
infected with force of infection β HHI , where β is the composite human-to-human transmission rate. Comparing the equilibria of the vector–host model and the SIR model
(Appendix A.2) provides β in terms of the parameters of the vector–host model:

β≈

mc2 βH βV
.
µV

(3.4)

SIR model (3.3) is a standard mathematical model for directly transmitted
pathogens like influenza and has been thoroughly analyzed (e.g. Hethcote, 2000).
The basic reproductive number is

R0 =

β
.
µH + γH

(3.5)

As with vector–host model (3.1), there are two equilibrium points, the disease-free
equilibrium and the endemic equilibrium: for R0 > 1 the disease-free equilibrium
is unstable and the endemic equilibrium is globally stable, while the disease-free
equilibrium is globally asymptotically stable for R0 ≤ 1 (with the endemic equilibrium
having HI < 0 and being unstable).
The unknown parameters are the transmission rate (β), the recovery rate
(γH ) and the probability of DHF (p), along with the initial proportion of humans
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recovered (hR (0) = HR (0)/H). As in the vector–host model, we used the fixed value
for the human mortality rate µH = 1/69 y−1 to simplify the parameter estimation.
Again, the initial proportion of infected humans is given by hI (0) = HI (0)/H(0) with
HI (0) = 454 and H(0) = 46 808 000. Like the vector–host model, the other initial
condition is hS (0) = 1 − hI (0) − hR (0).

3.2.4

Bayesian Markov chain Monte Carlo estimation
To estimate the unknown parameters, we used a Bayesian MCMC technique.

Bayesian inference uses prior information of the model parameters from previous
studies, which is then combined with new data to generate estimates in the form of a
probability distribution for the parameters. More precisely, for parameters θ and data
D, with the prior parameter distribution Pr(θ) and likelihood function Pr(D | θ), the
posterior parameter distribution Pr(θ | D) is given by Bayes’s Theorem:
Pr(D | θ) Pr(θ)
Pr(D)

(3.6)

Pr(θ | D) ∝ Pr(D | θ) Pr(θ).

(3.7)

Pr(θ | D) =

or, alternately,

Because there are no general closed-form solutions, MCMC or other methods must
be used to generate approximate samples from the posterior parameter distribution
Pr(θ | D).
The connection between the data and the parameters is made by the likelihood
function L(θ) = Pr(D | θ), which is the conditional probability of obtaining the data
(D) for the given parameter values (θ). Therefore, L(θ) needs to be maximized to
obtain best-fit parameter set. In our case, the likelihood function is derived from
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the vector–host and SIR models, the solutions to which provide estimates of the
DHF monthly incidence data. We added a compartment to each model to calculate
the cumulative number of DHF infections (HC ). We assumed that a fraction p of
infections were diagnosed as DHF, with p constant in time. We added differential
equations for the HC compartment,
VI
dHC
= pmcβH HS ,
dt
V

(3.8)

dHC
HI
= pβ HS ,
dt
H

(3.9)

for the vector–host model, and

for the SIR model, which are precisely the rates of new infections multiplied by p. The
“ode15s” function in Matlab was used to numerically solve the vector-host model (3.1)
& (3.8) and the SIR model (3.3) & (3.9). These numerical solutions give the predicted
monthly cumulative DHF incidence, yi = HC (ti )/H, where ti = 0, 30, 60, ... days.
Using the least-squares error between the cumulative DHF data Di and the model
prediction,
2

E =

15 
X

2
Di − yi (θ) ,

(3.10)

i=1

we assumed the errors were Gaussian, giving the likelihood function


L(θ) = Pr(D | θ) = exp −E 2 .

(3.11)

For the prior parameter distributions, we assigned wide uniform distributions,
with ranges chosen to represent our general understanding about where the parameter
values may lie. In the absence of any information on parameters estimates, we used
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least-squares fitting to find best-guess estimates of parameters. Estimates of γH , µV
and µH from the literature (γH = 1/7 d−1 , µV = 1/14 d−1 and µH = 1/69 y −1 ) were
used and the vector–host model was fitted to the data using least squares in Berkeley
Madonna to find initial point estimates βaH = 0.002, βaV = 1.8 and p = 0.04. We
used these initial point estimates to form uniform priors for these parameters such
that their point estimates lie inside the range of priors. For the transmission term β
of the SIR model, we simply choose a very wide uniform prior. Where parameters
were common to both models, both models used the same prior (Table 3.1).
To generate the posterior parameter distribution, we used an MCMC method
based on the Metropolis algorithm using a Gaussian jumping distribution with an
adaptive covariance matrix. For each model, we simulated 4 independent MCMC
chains and used the Gelman–Rubin test to determine when the chains had converged
to the stationary distribution, i.e. the parameter posterior distribution. The Gelman–
Rubin test signals convergence when the variance between independent chains is similar to the variance within the chains. (See section 2.1 for more details.) Once the
Gelman–Rubin test passed, we continued sampling from one of the chains for 10 000
more iterations without updating the covariance matrix, saving every 5th iterate as
the posterior parameter distribution.

3.3

Results
We estimated 7 total parameters for the vector–host model and 4 total pa-

rameters for the SIR model by Bayesian MCMC using the cumulative DHF incidence
data. Both models with their maximum-likelihood (ML) parameter estimates fit the
data well (Figure 3.3), with the vector–host model fitting slightly better. (More on
model fitting and model selection below.)
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The estimates of the human recovery rate were similar for both models (Figure 3.4(d) and Table 3.1). The average duration of human dengue infection is between 2 and 7 days approximately, with ML estimates of about 2 to 3 days. The
initial proportion of humans recovered (hR (0)) was estimated to be small in both
models, indicating that the human populations were almost entirely susceptible when
the outbreak started.
Estimates of the probability of DHF differed somewhat between models: ML
of around 3 DHF cases per 1000 infections from the vector–host model and around 14
DHF cases per 1000 infections from the SIR model. The vector–host model includes
several parameters not present in the SIR model. From the vector–host model, the
range of average lifespan of mosquitoes (1/µV ) was found to be approximately 13 to
26 days, with ML estimate of about 15 days. The initial proportion of mosquitoes
infected was very small (ML of about 0.5%), so that the outbreak had just started in
the mosquitoes as well as the humans.
The transmission rates are not common between the models, but comparison
of equilibria of both the models allowed us to compare the composite transmission rate
β from the SIR model with β = βaH βaV /µV for the vector–host model (Figure 3.4(c)).
Although, the ML estimates of β from both models are similar, the distribution from
the vector–host model has more weight at higher values of β than the distribution
from the SIR model: e.g. the median estimates are 0.4882 and 0.3243 respectively.
The basic reproductive number (R0 ), the expected number of secondary cases
produced by a single infection in a completely susceptible population, was calculated
using equations (3.2) and (3.5) for the respective models, for each MCMC parameter
sample (Figure 3.4(i)). For all parameter samples, R0 > 1 as expected since the
data show an epidemic, but the R0 values from the vector–host model (ML: 1.57) are
higher than from the SIR model (ML: 1.10).
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Figure 3.3: Fits of the vector–host and SIR models. Shown are the cumulative DHF
cases from the data (black circles), and from the models with the maximum–likelihood
parameter estimates (thick black curves) and 20 samples from the posterior parameter
distribution (thin color curves).
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Parameter
−1

Model

ML

Posterior
Median

90% CI

U (0, 1)

VH

0.0686

0.0521

(0.0146, 0.2241)

U (0.1, 2)

VH

0.4307

0.4867

(0.1299, 1.6821)

VH
SIR
VH
SIR
VH
SIR
VH
SIR

0.4881
0.5718
0.3104
0.5211
0.0028
0.0137
—
—

0.4882
0.3243
0.2480
0.2650
0.0022
0.0057
—
—

(0.2782, 0.9364)
(0.1931, 0.5805)
(0.1521, 0.4440)
(0.1347, 0.5315)
(0.0010, 0.0086)
(0.0018, 0.0354)
—
—

U (0.01, 0.1)

VH

0.0605

0.0531

(0.0378, 0.0781)

U (0, 1)

VH
SIR

0.0067
0.0332

0.0020
0.0019

(0.0000, 0.1320)
(0.0000, 0.1363)

U (0, 1)

VH

0.0009

0.0005

(0.0000, 0.0056)

—

VH
SIR

1.5724
1.0972

1.9733
1.1989

(1.3556, 3.2059)
(1.0523, 1.5243)

Prior



βaH d
Mosquito-to-human
transmission rate

βaV d−1
Human-to-mosquito
transmission rate

β d−1
Composite
 transmission rate
γH d−1
Human recovery rate
p
Probability
 of DHF
−1
µH y
Human mortality
rate

µV d−1
Mosquito mortality rate
hR (0)
Initial humans recovered
vI (0)
Initial mosquitoes infected
R0
Basic reproductive number

U (0, 10)
U (0.1, 0.6)
U (0, 0.1)
1/69

Table 3.1: Posterior summary of parameter estimates. For simplicity, µh was not
estimated. R0 is not a parameter, but rather a function of the other parameters.
U (a, b) is the uniform distribution between a and b. For parameters common to
both models, the same prior was used for both models. “ML” is maximum-likelihood
estimate; “CI” is credible interval; “VH” is the vector–host model. Parameter units
are given in parentheses.
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Because R0 is an important metric for an infectious disease, we performed uncertainty and sensitivity analysis of R0 for both models using partial rank correlation
coefficients (PRCC). The PRCC measures the independent effect of each input parameter on R0 , assuming the parameters to be independent (Blower and Dowlatabadi,
1994). The ordering of these PRCCs directly corresponds to the level of statistical
influence, the impact that uncertainty in the estimate of a parameter has on the
variability of R0 (Sanchez and Blower, 1997). We used the “prcc” function of the R
library epiR (Stevenson, Accessed March 10, 2013).
For both models, all of the parameters were significantly different from 0
(p-value < 2.5 × 10−135 ). For the vector–host model, all parameters except hR (0)
and vI (0) were most influential in determining the magnitude of R0 (|PRCC| > 0.5),
while only β and γH for the SIR model were most influential on the magnitude of
R0 . A positive PRCC value indicates that an increase in that parameter leads to an
increase in R0 , while a negative value shows that increasing that parameter decreases
R0 . For the parameters that appear explicitly in the R0 equations (3.2) and (3.5),
the signs of the PRCCs were as expected. Of the remaining parameters, p and vI (0)
have a negative influence on R0 , while hR (0) has a positive influence on R0 .
Parameter estimates for both models suggest that the initial proportion of
humans recovered and the initial proportion of vectors infectious are very small. As
a result, we tried fitting both models by fixing hR (0) = 0 and vI (0) = 2hI (0) and
estimating the other parameters in order to decrease the complexity of the models
(Figure 3.6). We fit the vector–host model by fixing hR (0) only, fixing vI (0) only and
fixing both hI (0) and vI (0). Similarly we fit the SIR model by fixing hR (0).
We used the Akaike Information Criterion (AIC) to compare the competing
6 models (Table 3.2). The AIC is a measure of the relative goodness of fit of a statistical model, balancing fit with number of parameters, finding the simplest model
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450

Model
Vector–host
Vector–host, vI (0) fixed
Vector–host, hR (0) fixed
Vector–host, hR (0) & vI (0) fixed
SIR
SIR, hR (0) fixed

df
7
6
6
5
4
3

Loglikelihood
−0.0779
−0.6847
−0.1173
−0.5835
−0.1020
−0.2173

AIC
14.1559
13.3695
12.2346
11.1669
8.2039
6.4347

∆AIC
7.7212
6.9348
5.7999
4.7322
1.7692
0

Akaike
weight
0.0130
0.0193
0.0341
0.0581
0.2558
0.6196

Table 3.2: Comparison of the vector–host and SIR models with and without fixed
initial conditions. “df” is degrees of freedom, i.e. number of parameters.

that best approximates the true, but unknown mechanisms generating the data. The
SIR model with fixed hR (0) had the minimum AIC value, implying this model was
the best among the models. The difference in AIC between the best model and the
others (∆AIC) gave “considerably less support” for all the vector–host models and
“substantial support” for both SIR models (Burnham and Anderson, 2002). Alternatively, Akaike weights provide the probability that a model is the best among the set
of candidate models. The Akaike weight for the SIR model with fixed hR (0) gave 62%
probability of it being the better model whereas the SIR model where hR (0) is also
estimated was 26% likely to be the better model. There was only a 12% probability
that any of the vector–host models was best.

3.4

Discussion
The fitting of dengue incidence data from Thailand to simple vector–host and

SIR model provided estimates of model parameters. The estimates of human recovery
rate from both the models suggest a recovery period of 2 to 7 days, which is consistent
with the estimates used in previous studies (Cummings et al., 2005; Gubler, 1998a).
The estimates of the probability of DHF from the vector–host model and the SIR
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model are that about 3 and 14 out of 1000 infections develop into DHF, respectively
for the two models. Based on the annual number of dengue infections and DHF cases
(Gubler, 1998a), 5 out of 1000 infections develop into DHF.
The ML estimate of the basic reproductive number (R0 ) for the SIR model is
30% smaller than the estimate for the vector–host model. This is driven by the recovery rate (γH ) being estimated as 68% larger in the SIR model. The MLE probability
of DHF (p) is 4.9 times larger for the SIR model. The two models—one with high
R0 and low p, the other with low R0 and high p—both fit the data well. The PRCC
result showing a negative influence of p on R0 confirms the relationship between these
two parameters.
Dengue had been causing annual outbreaks in Thailand for some time prior
to the 1984 epidemic (Nisalak et al., 2003). Despite this, our estimates of the initial proportion of people immune (hR (0)) from both models are very small. A high
birth rate (United Nations, Accessed March 25, 2013) and the reemergence of dengue
serotypes 3 and 4 (Nisalak et al., 2003) could explain this low immunity. In addition,
mosquito seasonality may be important to explain the monthly variation in dengue
incidence (Wearing and Rohani, 2006), and keeping the mosquito population constant
for simplicity in our model could have contributed towards small estimates of hR (0).
The vector–host model fits the data slightly better than the SIR model, but
the fewer number of parameters results in the SIR model being strongly selected by
the AIC. Alternative measures for model selection like the Bayesian Information Criterion and the Deviance Information Criterion more strongly penalize the number of
parameters than AIC, so we expect the result of model selection to remain unchanged.
This suggests that incorporating mosquito populations explicitly in dengue models
may not be necessary to estimate incidence.
We believe that for any vector-borne pathogen, explicitly including vector
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populations may generally be unnecessary to model prevalence or incidence in human
or other primary host. We expect that models with and without explicit vectors
will fit primary-host data about equally well and then the fewer parameters of the
model without explicit vectors will result in it being preferred by formal model selection. Other factors like seasonality in mosquito abundance may be crucial to fit some
long-term data (e.g. Figure 3.1), which could result in explicit-vector models fitting
the data significantly better than implicit-vector models. In addition, explicit-vector
models are necessary when interventions are targeted at the disease vector, e.g. insecticide or genetically modified mosquitoes. When the desired model output is the
effectiveness or cost-effectiveness of an intervention that acts on the primary host,
our result suggests that implicit-vector models are likely to be sufficient.
The composite transmission parameter (β) for the vector–host model was obtained from the equilibria of the two models and may not be a good approximation
for our comparison of the dynamics of the models. This may explain the difference in
the estimates of the composite transmission parameter (β) between the two models.
This is reinforced by the fact that the SIR model fits the observed data well, but not
for the same β values as the vector–host model. Thus, in addition to being preferred
by model selection, use of the SIR model is justified when only the equilibrium values
are of interest.
We chose to use DHF cases because the data was available monthly, while we
are only aware of annually reported DF cases (Nisalak et al., 2003). Moreover, a
person infected with DHF is more likely to visit hospital due to the severity of the
disease, and so more likely to be diagnosed and reported. Therefore, data on reported
DHF cases may be more accurate to actual DHF cases than DF data is to DF cases.
We used a Bayesian MCMC technique for estimation, though other estimation
methods have also been used in the literature. In particular, least-squares error
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fitting is popular (e.g. Mubayi et al., 2010) and the expectation maximization (EM)
algorithm has seen some use (Duncan and Gyöngy, 2006; Lavielle et al., 2011). We
choose Bayesian MCMC approach as it provides a huge amount of modeling flexibility
and enables analysis of all the model parameters or functions of parameters. It
also has advantage of providing a complete distribution for parameters as posterior
distributions instead of point estimates. Moreover, posterior summaries such as mean,
medians, maximum likelihoods, maximum, minimum and credible intervals are easy
to obtain as well.
In this study, we fitted dengue incidence data from Thailand to vector–host and
SIR models and obtained estimates of model parameters including average duration of
dengue infection in humans, lifespan of mosquitoes and the probability of the severe
form of disease. The parameter estimates were consistent with existing published
values and PRCC values showed that all the parameters except initial conditions have
significant influence on the magnitude of the basic reproduction number R0 . Both the
vector–host model as well as the SIR model fit the incidence data well, however AIC
model selection found the SIR model with fixed hR (0) to be substantially better than
the vector–host model, implying that incorporating mosquito population explicitly in
a dengue model may not be necessary to explain the incidence data from Thailand.
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Chapter 4
The role of population immunity
for accurately estimating model
parameters for dengue
transmission
4.1

Introduction
The basic reproduction number (R0 ) is defined as the number of secondary

cases that one case would generate on average over the course of its infectious period
in a completely susceptible population (Heffernan et al., 2005). R0 is a useful metric
to determine whether or not an infectious disease can spread through a population.
The outbreaks of epidemics and the persistence of endemic levels of an infectious
disease are associated with R0 > 1 (Heffernan et al., 2005). More specifically, when
R0 > 1 each infectious case generates more than one new infectious case and so
infection would be able to invade the susceptible population, whereas for R0 < 1,
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each infectious case generates less than one new infectious case and therefore infection
would be cleared from the population. This threshold allows one to determine the
amount of effort that is necessary to prevent an epidemic or to eliminate a disease from
a population. The estimation of R0 has proved to be very critical in understanding
the outbreak and spread of infectious diseases, for example severe acute respiratory
syndrome (SARS) (Choi and Pak, 2003), West Nile virus (Wonham et al., 2004), foot
and mouth disease (Ferguson et al., 1999c), dengue (Luz et al., 2003) and malaria
(Hagmann et al., 2003). The value of R0 varies considerably for different infectious
diseases, as well as in different populations, as it depends on the duration of infectious
period, the probability of transmission of infection per contact and the number of
new susceptible individuals contacted per unit time. As a result, it is important to
estimate R0 for a given disease in a particular population.
Dengue, a mosquito-borne viral disease of tropical and sub-tropical regions
around the world, poses a substantial health burden on the population in Thailand
(Clark et al., 2005). Dengue fever and dengue hemorrhagic fever (DHF) are among
the leading causes of hospitalization of children in Thailand and southeast Asia generally (Clark et al., 2005). Several studies have estimated the basic reproduction
number and used it to understand the spread and dynamics of dengue transmission
in Thailand (Adams et al., 2006; Chao et al., 2012; Cummings et al., 2009; Nagao
and Koelle, 2008). The estimates of the reproduction number of dengue in Thailand
vary considerably between these studies, from values of around 1–3 (Adams et al.,
2006; Chao et al., 2012) to 6.7 (Cummings et al., 2009) to 10–12 (Nagao and Koelle,
2008). More recently, we fitted standard dengue models to monthly observed DHF
cases in Thailand in 1984 using Bayesian MCMC and found R0 estimates in the range
1–3 (Pandey et al., 2013). This variability in R0 estimates among different studies
is not well understood and may possibly be attributed to the complex dynamics of
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dengue due to interactions of its 4 different serotypes (Adams et al., 2006; Chao et al.,
2012; Cummings et al., 2009; Nagao and Koelle, 2008). In addition, different methods
of estimating R0 may contribute to the variability (Heffernan et al., 2005; Li et al.,
2011).
In the present study, we fit a simple SIR-type deterministic model to monthly
DHF cases in Thailand in 1984 to investigate the variability in the basic reproduction
number for dengue. We found that that our model fits the observed data evenly for
varying values of the basic reproduction number as other parameters vary. Specifically, there was a logarithmic type relationship between the level of initial population
immunity and the basic reproduction number that suggests difficulty in estimating
the level of population immunity and the basic reproduction number together from
same data source. Thus, in order to estimate the model parameters accurately, either
the basic reproduction number or the proportion of the population immune at the
beginning of the epidemic must be estimated from separate data.

4.2

Model and Approach
We used a standard SIR-type deterministic dengue model (Hethcote, 2000). As

we are only interested in infections in humans, we did not model mosquito population
explicitly (Pandey et al., 2013). The model consists of three compartments, one each
for the number of people susceptible (HS ), infectious (HI ) and recovered (HR ). The
model is the system of differential equations
HI
dHS
= BH − β HS − µH HS ,
dt
H
dHI
HI
= β HS − γH HI − µH HI ,
dt
H
dHR
= γH HI − µH HR ,
dt
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(4.1)

where H = HS + HI + HR is the human population size. A susceptible person
gets infected with force of infection β HHI , where β is the composite human-to-human
transmission rate (Pandey et al., 2013). The average duration of infection is 1/γH
and 1/µH is the average lifespan of people in Thailand. Since we only fit the model
to an epidemic lasting a year, we assumed the population size is constant by setting
the birth rate equal to the death rate, BH = µH H. The basic reproduction number
is
R0 =

β
.
µH + γH

(4.2)

We obtained the monthly incidence of DHF for Thailand from 1983 to 1997
(Johns Hopkins Center for Immunization Research, Accessed January 14, 2013). We
choose the 1984 epidemic as a clear, representative example among this data. Since
cumulative incidence is generally smoother and thus easier to fit, we used the cumulative monthly number of DHF cases for the period January 1984 to December 1984.
We added a compartment to our model (4.1) to calculate the cumulative number of
DHF infections (HC ). We assumed a fraction p of infections were diagnosed as DHF,
with p constant in time. The differential equation for the HC compartment is
HI
dHC
= pβ HS ,
dt
H

(4.3)

which is precisely the rate of new infections multiplied by p.
The unknown parameters are the transmission rate (β), the recovery rate (γH )
and the probability of DHF (p), along with the initial proportion of people immune
(hR (0) = HR (0)/H). As we are interested in the variability in reproduction number
R0 , we reparametrized our model using (4.2) to avoid estimating β directly. For
simplicity, we fixed µH = 1/69 y−1 based on the average human duration of life
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in Thailand in 1984 of about 69 years (World Bank, Accessed January 14, 2013).
We used the first month of the incidence data (January 1984) to calculate initial
conditions for the initial population infected, HI (0) = 454. Since the population is
constant, the initial susceptible population was calculated as HS (0) = H(0)−HI (0)−
HR (0) where H(0) = 46 806 000 is Thailand’s population in 1984.
We used the “ode15s” function in Matlab to numerically solve the model
(4.1) and (4.3) to generate the predicted monthly cumulative DHF incidence, yi =
HC (ti )/H, where ti = 0, 30, 60, ... days. Using the least-squared error between the
cumulative DHF data Di and the model prediction yi (θ) for the input parameter
values θ,
E2 =

12 
X

2
Di − yi (θ) ,

(4.4)

i=1

we assumed the errors were Gaussian, giving the loglikelihood function

Loglik(θ) = log (Pr(D | θ)) = −E 2 ,

(4.5)

which is log of the conditional probability of obtaining the data (D) for the given
parameter values (θ).
For our simulations, we varied R0 from 1 to 20 and sought optimal estimates for
rest of the unknown parameters (γH , p and hR (0)) that maximize the likelihood function (4.5). For a given value of R0 , we used the Matlab function “fminsearchbnd”,
which first transforms the problem into an unconstrained problem and then uses
Nelder–Mead smilex direct search to minimize the negative of the loglikelihood function over the rest of parameters while remaining within the wide bounds that were
chosen for rest of the parameters based on on our past work (Pandey et al., 2013) to
represent our general understanding about where the parameter values lie (Table 4.1).
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Parameter
BH
µH
γH
p
hR (0)
R0

Definition
Value
−1
birth rate (y )
1/69
−1
per capita mortality rate (y )
1/69
recovery rate (d−1 )
(0.125, 1)
proportion of dengue infections that become DHF
(0, 0.1)
initial proportion of people immune
(0, 1)
basic reproduction number
(1, 20)
Table 4.1: Parameters of the dengue model.

For each R0 value, we ran our simulation from 11 random initial conditions to ensure
that algorithm did not get stuck at local minima and saved the parameter values that
resulted in the best loglikelihood value. For some values of R0 , the method found
suboptimal local maxima, so we used Matlab’s function “smooth” to implement a
3-point moving average to smooth our results in order to highlight the overall trend.

4.3

Results
For values of the basic reproduction number from 1 to 20, we found optimal es-

timates of the remaining model parameters: recovery rate (γH ), proportion of dengue
infections that develop DHF cases (p) and the initial proportion of humans immune
(hR (0)).
We found good fits for varying values of R0 (Figure 4.1). With increasing values
of R0 the likelihood increases as well, but the model fits appear similar (Figure 4.2).
As R0 varied from 1 to 20, the optimal estimates for recovery rate (γH ) decreased from
around 0.6 and stabilized around 0.3 (i.e., the average duration of dengue infection
varied from around 2 days to 3 days) (Figure 4.3a). Similarly, the optimal estimates
for proportion of dengue infections that develop DHF cases (p) varied from 0.02 to 0.08
(Figure 4.3b). Equally good fits (similar likelihoods) are achieved for higher R0 values
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Figure 4.1: Maximum of loglikelihood for R0 from 1 to 20. The maximum of loglikelihood corresponds to the maximum likelihood. A 5-point moving-average method
was used for smoothing.

at relatively smaller recovery rate (γH ) estimates and relatively larger probability of
DHF (p) estimates, but the variation in the estimates is not large and is consistent
with existing estimates (Cummings et al., 2005; Gubler, 1998a).
The estimates of the initial proportion of people immune hR (0) increased as
R0 increased (Figure 4.3c). Moreover, the variation in hR (0) was very large as hR (0)
increased from values of around 0.16 to 0.96. Immunity in around 15% of population
at the beginning of the epidemic resulted in R0 of 1 to 2, whereas immunity in more
than 90% of population at the beginning of the epidemic resulted in large reproduction
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Figure 4.2: Model fit with optimal parameter estimates for R0 = 1.3 and 17.6. Black
dots are cumulative Thailand DHF incidence data. Blue and green lines represent
the model fits corresponding to R0 = 1.3 and 17.6 respectively.
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Figure 4.3: Variations in optimal parameter estimates as the basic reproduction number R0 varies. A 5-point moving-average method was used for smoothing.
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Figure 4.4: Maximum of loglikelihood for varying R0 and hR (0) values.

numbers (R0 > 11). This relationship between the level of population immunity at
the beginning of the epidemic and the basic reproduction number was clear when we
found the maximum likelihood for varying R0 and the proportion of humans immune
hR (0) together and maximized likelihood over the remaining parameters (γH and p)
(Figure 4.4).
This connection between R0 and hR (0) can be further explored by assuming
that dengue incidence has reached a steady-state. We found a relationship between
the initial proportion of humans recovered hR (0) and the cumulative number of infections after the end of one year (details in Appendix B), The balance between birth,
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Figure 4.5: Optimal estimates of hR (0) and h∗R for varying R0 values.

death and infection gives

h∗R =

(HC (1) − HC (0))γH
(µH + γH )pµH H

(4.6)

where h∗R is the proportion of people immune when system is at steady-state. For
varying basic reproduction number, we plotted the optimal estimates of the initial
proportion of humans immune (hR (0)) at the beginning of 1984 and h∗R calculated
using the optimal estimates of the rest of the model parameters, human population
(H = 46 806 000) in 1984 and fixed µH = 1/69 y −1 . We found that system is not in
steady–state for the observed data for R0 between 1 to 20 (Figure 4.5).
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4.4

Discussion
We found that equally good fits of our standard dengue model to 1984 monthly

DHF incidence data from Thailand can be achieved for wide range of R0 values. As
R0 varied, the other parameters also varied to generate similar maximum likelihoods.
The largest variation in optimal parameter values was found in the initial proportion
of people immune (hR (0)). hR (0) increased from low values of around 0.16 for R0 in
the range of 1 to 2 to high values of about 0.96 for R0 > 11. The relationship between
hR (0) and R0 means that when estimating parameters using observed data, low levels
of the initial population immunity are consistent with lower values for R0 , whereas
high levels of population immunity are consistent with higher values for R0 . The
role of the level of initial population immunity in determining estimates for the basic
reproduction number seems justified as for high levels of the population immunity, the
disease needs to be more infectious and thus will have higher reproduction number
in order to generate the same number of infections in the the population, compared
to when the level of the initial population immunity is low.
Our results highlight the importance of finding the immunity level in population in order to estimate the rest of the parameters. In other words, choosing
inaccurate estimates for the level of initial population immunity to estimate R0 may
fit the data well, but may not give correct values. In order to estimate model parameters accurately, it is vital that we use an estimate from another source for the level
of initial population immunity or for the basic reproduction number. It is difficult
to know the level of population immunity for any pathogen and 4 different dengue
serotypes circulating in Thailand make it even more challenging. Specific data that
classifies dengue incidence by serotype along with the knowledge of dengue serotypes
circulating in the population at present and in prior years may be used to find reason-
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able estimates for the level of population immunity at the beginning of the epidemic.
The optimal estimates of the duration of infection (1/γH ) and the proportion
of dengue infections that develop DHF cases (p) increased with increasing values of
R0 . The variation in both of these parameters was not large, as the optimal estimates
for the duration of infection varied between about 2 to 3 days and the variation in
the number of DHF cases per 100 dengue infections was between 2 and 8.
Based on the assumption that the epidemic has already reached steady-state
and using the optimal estimates for initial population immunity, we found that for
the 1984 epidemic in Thailand, the population immunity levels were not consistent
with the basic reproduction number between 1 to 20 meaning either the system is not
in steady-state for the observed data or the it has a R0 higher than 20. We believe
the system has not reached the steady-state for the DHF incidence data in Thailand.
As the transmission parameter (β) depends on the biting rates of mosquitoes,
and probabilities of transmission, it is difficult to estimate a range of values for this
transmission parameter. Thus, we avoided estimating β by reparametrizing the model
in terms of R0 . For our simulations, we varied R0 from 1 to 20 to ensure a wide range
that includes values for dengue transmission that have been used or estimated in the
literature.
The monthly DHF incidence data from Thailand in 1984 was used for this
study. However, our results do not change considerably when we chose epidemic data
from three different years (1985, 1987 and 1990). The likelihood in our study was
chosen on the assumptions that the errors follow a Gaussian distribution, but we
believe that we would get similar results if a different likelihood was chosen.
We used a standard SIR-type dengue model to investigate the reasons behind the wide variability in estimates of the basic reproduction number in Thailand.
We found that the initial population immunity plays a vital role in determining the
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estimate for R0 . Assuming a small initial population immunity results in lower estimates for R0 , whereas large initial population immunity gives higher values for R0 .
This relationship between the initial population immunity and the basic reproduction
number may be a reason for wide range of R0 estimates found in studies. Moreover,
finding better estimates of population immunity level would help to more accurately
estimate R0 and other epidemiological parameters for dengue.
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Chapter 5
The introduction of dengue vaccine
may temporarily cause large spikes
in prevalence
5.1

Introduction
Dengue is an RNA virus in the family Flaviviridae. There are four serotypes of

dengue virus, each of which induces a specific antigenic response in humans. Infection
with any of the four serotypes can cause disease ranging from dengue fever (DF)
to dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), in order of
increasing severity (Guzmán and Kouri, 2002). Infection with a serotype provides lifelong immunity to that serotype and an increased risk for the severe forms of disease
(DHF and DSS) during subsequent infection with a different serotype (Nagao and
Koelle, 2008). Dengue infection has been recognized in over 100 countries: DF and
DHF are important public-health problems, especially in the tropics and subtropics,
where nearly 2.5 billion people are at risk of infection (Guzmán and Kouri, 2002). An
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estimated 50 million cases of DF occur every year, including 500, 000 hospitalizations
for DHF (Guzmán et al., 2010).
Despite the expansion in geographic range of the virus over past four decades
(Beatty et al., 2012), there is no dengue vaccine licensed for use presently. Dengue
vaccine development is an area of active research: significant advances have occurred
in recent years and several vaccine candidates are showing promise in clinical studies
(Coller and Clements, 2011). The most advanced vaccine candidate showed efficacy
of 30% and protection against 3 of the 4 serotypes of dengue (Halstead, 2012). With
several dengue vaccine candidates progressing through clinical trials, a licensed dengue
vaccine is expected to be available in less than 10 years (Guzmán et al., 2010).
Once the vaccine becomes available, policy makers will have to decide how
to best allocate it. As a result, it is imperative to carefully examine the effects of
vaccine-allocation policies. Mathematical models of dengue transmission predict complex temporal patterns in prevalence, driven by seasonality in mosquito abundance
(Reich et al., 2013), and may include a transient period immediately after vaccine
introduction where prevalence can spike higher than in the pre-vaccine period. An
increase in infections, however brief, can raise doubts about the vaccination program,
while the longer-term outcome may be highly favorable. A temporary increase in
infections might lead to public doubts and refusal to use the vaccine or even policy
makers’ ending the vaccination program altogether. Moreover, these spikes can also
pose serious problems by overwhelming resources like available hospital beds. Thus,
investigating short- and long-term effects of the vaccination introduction is important.
In the present study, we found that simple dengue transmission models frequently predict large transient spikes in prevalence in the years after vaccination is
begun. These presence of these spikes was highly sensitive to the level of vaccination,
the efficacy of the vaccine, and the timing of the vaccination program. Despite the
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presence or absence of transient spikes, vaccination reduced dengue infections when
averaged over a the first 15 years after vaccine introduction and when averaged over
the very long term.

5.2

Methods and Approach
Here we briefly describe the mathematical models for dengue transmission that

we used in this study. See Appendices C.1–C.3 for detailed descriptions of the models.
We developed standard SIR-type deterministic dengue models to explore the
short- and long-term effects of vaccine introduction. In the models, the population was
divided into unvaccinated and vaccinated people, and then each of these was further
divided by infection history (Figure 5.1). In the main model, a person with no prior
dengue infection (state S1) can have a primary infection from any serotype of dengue
(I1), recovery from which provides him with life-long immunity to that serotype (S2).
He can then acquire infection from any of the remaining three serotypes, and enter
the secondary-infection class (I2). Third or fourth infection from dengue is very rare
(Halstead, 2003), so we assumed that an individual recovering from secondary infection becomes immune to all serotypes (R). Dengue mortality in humans is at most
1–2% (Rajapakse, 2011) and thus ignored in our model for simplicity. As we are only
interested in infections in humans, we did not model mosquito population explicitly
(Pandey et al., 2013). We used model parameters consistent with the literature, along
with a small level of seasonal forcing of transmission to capture seasonal oscillations
in mosquito population size (Nisalak et al., 2003).
We modeled the vaccine as having efficacy φ at preventing infection. The
vaccination program was modeled as having two possible components: one component
vaccinates a proportion p of infants, and the other component vaccinates people in
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Figure 5.1: Diagram of the main model. U denotes unvaccinated people, while V denotes vaccinated. S1 and S2 are people susceptible to primary and secondary dengue
infection, respectively. I1 and I2 are people infected with primary and secondary
infection, respectively. R is people recovered from secondary infection and immune
to further infections. See Table C.1 for definition of the other symbols.

the general population at rate v. For simplicity, for the main results we used only
vaccination of infants (v = 0).
To simulate vaccine introduction, we computed a solution to the model with
no vaccine (p = 0) from arbitrary initial conditions until it converged to regular
periodic oscillations (a stable limit cycle, in mathematical terms (Strogatz, 1994)).
From a new initial point on this periodic solution, we then computed the solution to
the model with vaccine introduced (p > 0).
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5.3

Results
The model prevalence converged to regular periodic oscillations, with or with-

out vaccination (e.g. Figure 5.2). Without vaccination, prevalence oscillates with a
period of 2 years. The perturbation caused by the introduction of vaccine results in a
transient period where the prevalence has not yet converged to periodic oscillations.
During this transient period, large spikes can occur, to levels above those present
before the vaccine was introduced, and this transient period may last many years.
For example, vaccinating 78% of infants at 30% vaccine efficacy results in an
initial period of about 60 years when prevalence can spike more than twice as high
as before vaccine introduction (Figure 5.2). After the transient period, prevalence
converges to annual oscillations with a smaller maximum than in the 2-year oscillations prior to vaccine introduction (Figure 5.2(C)). In contrast, vaccinating instead
90% of infants results in a transient period of about 70 years, where prevalence can
spike more than three times as high as before vaccine introduction, and prevalence
then settles down to 3-year oscillations with a higher maximum than before vaccine
introduction (Figure 5.3).
These two examples show that the effectiveness of a vaccination program may
differ depending on exactly what is evaluated. Effectiveness may consider individual
points in time (e.g. the height of the spikes in prevalence) or periods of time (e.g. total
number of infections in a fixed period). In addition, effectiveness may be evaluated
over the period just after vaccine introduction or, as is more convenient from a modeling perspective, the period after the prevalence has converged to periodic oscillations.
To capture the transient period over many simulations, we considered the transient
period to be the first 15 years after vaccine introduction. To quantify the severity of
transient spikes at any point in time, we calculated the maximum prevalence during
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Figure 5.2: Simulated dengue prevalence after vaccine introduction. Starting at year
t = 0, p = 78% of infants are vaccinated with a vaccine of efficacy φ = 30%. The
black curves are prevalence after vaccine introduction, while the gray curves are the
prevalence had vaccine not been introduced. (A) shows prevalence for 150 years after
vaccine introduction, while (B) & (C) show only the first and last 15 years of this
period. See subsection C.1 for model & parameter definitions.
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Figure 5.3: Simulated dengue prevalence after vaccine introduction. The model and
parameter values are as in Figure 5.2, but with p = 90% of infants vaccinated.
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first 15 years after introduction of the vaccine. To examine the effectiveness over
a period of time, we also calculated the total number of infections during the first
15 years after vaccine introduction. For the period after prevalence has converged
to periodic oscillations, we calculated both the maximum prevalence and the mean
prevalence per year.
To explore the transient spikes in prevalence, we varied vaccine coverage (p), for
low (φ = 30%) and high (φ = 70%) vaccine efficacy (Figure 5.4(A)). Large transient
spikes (i.e. above the pre-vaccine maximum of about 2 per thousand) were present
after vaccine introduction for both levels of vaccine efficacy. Moreover, for the higher
vaccine efficacy, large transient spikes appeared at lower vaccine coverage.
By varying vaccine efficacy, we found that large transient spikes occur particularly when vaccine efficacy is neither very low nor very high (Figure 5.5). For 80%
vaccine coverage, when vaccine efficacy is below 30%, the perturbation caused by vaccine introduction is insufficient to generate transient spikes. On the other hand, when
vaccine efficacy is higher than 97% at 80% vaccine coverage, vaccination quickly reduces prevalence without large transient spikes. Similarly, with 40% vaccine coverage,
there are no large transient spikes below 58% or above 96% vaccine efficacy.
Since prevalence oscillates with a period of 2 years without vaccination, we
varied the time of vaccine introduction over the 2-year period (Figure 5.6). The presence or absence of large transient spikes after vaccine introduction is highly sensitive
to the time of vaccine introduction.
Despite the presence of large transient spikes in prevalence, the total number
of infections over the first 15 years was lower with vaccine than without in all of
the simulations we performed (Figure 5.4(B)). However, we cannot rule out that the
initial burden may be higher in some cases, especially over shorter time spans than
15 years. Moreover, higher vaccine efficacy yields higher drop in the initial burden at
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Figure 5.4: Effectiveness of the vaccination program at different levels of coverage.
(A) Maximum prevalence in the first 15 years after vaccine introduction. (B) Total
number of infections over the first 15 years after vaccine introduction. (C) Long-term
mean annual incidence.
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Figure 5.5: Maximum prevalence over the 15 years after vaccine introduction for varying vaccine efficacy. p = 80% (cyan) and p = 40% (magenta) of infants are vaccinated.
The dashed gray line is the maximum prevalence prior to vaccine introduction.
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Figure 5.6: Maximum prevalence over the 15 years after vaccine introduction for
varying time of vaccine introduction. p = 80% of infants are vaccinated with a
vaccine of efficacy φ = 30% (blue) and φ = 70% (red). The time that the vaccination
program begins was varied from the beginning (t = 0) to the end (t = 2) of the 2-year
cycle in prevalence that exists when there is no vaccine. The dashed gray line is the
maximum prevalence prior to vaccine introduction.
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constant vaccine rates. Thus, although the presence of large transient spikes may pose
immediate problems by overwhelming the resources, over a 15-year period, vaccination
reduces infections.
After the transient period caused by vaccine introduction, prevalence converges again to a regular periodic oscillation, but the oscillation may have a different
period and the maximum prevalence may be lower or higher than prior to vaccine
introduction (e.g. Figures 5.2(C) & 5.3(C)). In all of our simulations, we found that
in the long-term, the mean annual incidence decreased as vaccine coverage increased
(Figure 5.4(C)). Although some vaccine introductions did lead to long-term prevalence with a higher maximum, their period was longer, so that the mean over many
years was always lower than without vaccine. Moreover, as expected, long-term mean
annual incidence was lower for higher vaccine efficacy.
The model also showed large transient spikes in prevalence when we modeled
vaccination programs in the whole population rather than just infants (p = 0 & v > 0)
and vaccination programs that combine the two (p > 0 & v > 0). We also tested
simpler and more-complex dengue models. The simpler model assumed that there are
no secondary infections, so that and individuals who recover from their first infections
move directly to recovered class (subsection C.2). Our more-complex model included
a period of short-term cross-protection after primary infection (Wearing and Rohani,
2006) (subsection C.3). Both models exhibited the potential for large transient spikes
(Figure 5.7).

5.4

Discussion
Using mathematical models of dengue transmission, we found that vaccine

introduction may lead to a transient period when infection prevalences spike higher
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Figure 5.7: Transient prevalence spikes in simpler (A) and more complex (B) dengue
models. (A) p = 80% of infants are vaccinated and the remainder of the population
is vaccinated at a per-capita rate of v = 0.6 per year. See subsection C.2 for model
& parameter definitions. (B) p = 60% of infants are vaccinated and the remainder of
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is φ = 70% in both models. See subsection C.3 for model & parameter definitions.
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than in the pre-vaccine period. These spikes in infection prevalence may pose serious
problems by overwhelming health resources like hospital beds, as well as create doubt
about the efficacy of the vaccination program. In our models, the presence of large
spikes required that vaccine coverage and vaccination efficacy were not both very
low or both very high. The occurrence of large transient spikes for lower vaccine
coverage and higher vaccine efficacy suggests that a sufficiently large perturbation to
the system is required in order for large transient spikes. These perturbations are
generated by the combination of vaccine coverage and vaccine efficacy. When vaccine
coverage and efficacy are both very high, the vaccination program reduces prevalence
so quickly that no spikes appear.
We also found that the presence or absence of large transient spikes was highly
sensitive to the time when the vaccine program is first begun. Indeed, the results are
so sensitive to introduction time, and likely also to changes in parameter values or
model structure, that we do not believe that model results can be used to minimize
the chance of large transient spikes.
Despite the presence of large transient spikes in prevalence, the total number
of infections over the first 15 years after vaccine introduction was always less than in
the 15 years prior to vaccine introduction. The decrease in infections was higher for
higher efficacy as well as for higher vaccine coverage. Likewise, in the long term, the
mean number of infection per year was always smaller than during the pre-vaccine
period and decreases with increasing vaccine coverage and vaccine efficacy.
Vaccination reduces the susceptibility of the population, but the short-term
interaction of the change in susceptibility with the seasonal forcing of the mosquito
population causes complex results, including large transient spikes. When averaged
over longer times, the impact is as expected: both the number of infections in the
15-years following vaccine introduction and the long-term mean annual were always
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found to be lower after vaccine introduction than before.
Large transient spikes after vaccine introduction were frequent for our main
model, along with simpler and more-complex models that we also tested. In general,
we believe that the occurrence of large transient spikes in response to perturbation is
a robust phenomenon of seasonally forced epidemic models. We are unaware of any
theoretical research on the short-time transient behavior of seasonally forced epidemic
models, however there is a rich literature on the long-time behavior of such models
(Grenfell et al., 2001; Keeling and Grenfell, 1997; King and Schaffer, 1999; King et al.,
1996).
In our models, we have used generic parameter values rather than those for a
specific location. In particular, different parameter values may change the period and
maximum amplitude of the pre-vaccine oscillation (King and Schaffer, 1999; Nagao
and Koelle, 2008). However, because of the robustness of the appearance of large
transient spikes in prevalence, we expect that these spikes would continue to appear
for different parameter values. Similarly, we expect large transient spikes would also
be present 1.) if the vaccination program were modeled as starting gradually rather
than instantaneously, 2.) if the human population were growing rather than remaining
constant size and 3.) if the vaccine were introduced at a state other than regular
periodic oscillation.
We used mathematical models to evaluate the short- and long-term effects
of introducing a dengue vaccine. We found that vaccine introduction may lead to
a transient period when infection prevalences spike higher than in the pre-vaccine
period. We believe such transient spikes are robust to changes in parameters and
model structure, and thus must be accounted for in planning vaccination programs
because they may overwhelm health resources. Despite the presence of transient
spikes, the vaccination program is likely to be effective at reducing the total number of
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infections during the first few years after introduction, as well as decreasing infections
in the long term. Policy makers should be prepared for transient spikes to mitigate
their burden and to accurately understand the effectiveness of the vaccine program.
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Chapter 6
Conclusions
In this dissertation, I studied different aspects of the mathematical modeling
of dengue transmission and vector–borne disease transmission in general. I developed
a novel method of Bayesian MCMC estimation for fitting disease models to observed
data. The Bayesian MCMC estimation is easy to implement and has the advantage
of giving a complete distribution for the parameters instead of point estimates, which
enables easy analysis of model parameters and functions.
Two distinct modeling approaches that have been extensively used to explain
dengue transmission were compared in order to explore how well dengue models under
different modeling assumptions explain observed incidence. I fitted the monthly DHF
cases of the year 1984 in Thailand to simple dengue models with and without explicitly
modeling mosquitoes using Bayesian MCMC estimation and compared their goodness
of fit by applying AIC model selection. Both models agreed with the data equally
well, so the model with implicit modeling of mosquitoes being simpler, was strongly
selected by AIC. Thus, incorporating mosquito population explicitly in dengue models
may not be necessary to explain the incidence data. The fitting of dengue transmission
data from Thailand to dengue models also provided estimates of model parameters like
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duration of dengue infection in human and probability of DHF that were consistent
with their corresponding estimates from the literature.
Based on results from my fitting of dengue models to observed incidence, as
well as other studies in literature, I found significant variability in the estimates of the
basic reproduction number (R0 ) for dengue transmission in Thailand. I investigated
this variability in R0 estimates among studies by fitting a standard dengue model to
dengue incidence for varying values of R0 and found a logarithmic type relationship
between the level of population immunity and the basic reproduction number. Particularly, choosing low levels of population immunity resulted in small R0 estimates
between 1 to 3, while larger R0 estimates (> 11) were obtained for high levels of population immunity. The variability in rest of the parameters of the model for varying
R0 values was not very large and their estimates were consistent with those in the
literature. I concluded that in order to estimate model parameters, particularly the
basic reproduction number, for dengue in Thailand accurately, it is necessary to use
appropriate estimates for the population immunity obtained from different data.
In consideration of a new dengue vaccine being expected within next 10 years,
I considered the short- and long-term impacts of vaccine introduction in a population.
Our particular focus was on the possibility of large transient spikes in prevalence immediately after vaccine introduction, driven by the perturbation to disease dynamics
due to vaccine introduction and seasonality in mosquito abundance. Using a simple
dengue transmission model, I found large transient spikes in prevalence to be a robust phenomenon that occurs as long as vaccine efficacy and coverage are not both
very high or very low. Although these spikes could lead to doubts about the vaccine
program in the public and decision makers and may overburden health resources like
hospital beds, the models predicted that vaccination does always reduce the total
number of infections in the 15 years after vaccine introduction. Thus policy makers
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should consider the possibility of transient spikes while making vaccine program and
to mitigate the burden of large spikes in prevalence and to accurately measure the
effectiveness of the vaccine program.
I outlined and demonstrated the method of Bayesian MCMC estimation to
estimate parameters of disease models. To explore how well dengue models under
different modeling assumptions explain observed incidence and to find good model
parameter estimates, I fitted the monthly DHF cases in Thailand to simple dengue
models with and without explicitly modeling mosquitoes using Bayesian MCMC estimation. Both models fitted the data well and so the simpler model was selected
strongly by AIC model selection. Thus I concluded that incorporating mosquito population explicitly in dengue models may not be necessary to explain the incidence data.
I investigated the wide variability in the basic reproduction number’s estimates for
dengue transmission in Thailand among studies by fitting a SIR-type dengue model
to dengue incidence for varying values of R0 . I found a logarithmic type relationship
between the level of population immunity and the basic reproduction number and
concluded that in order to estimate model parameters, particularly the basic reproduction number accurately, reasonable estimate of population immunity from another
source is necessary. Finally, using a simple dengue transmission model, I found that
introducing dengue vaccine may temporarily cause large spikes in prevalence when
vaccine efficacy and coverage are not both very high or very low. Despite the presence of these spikes, vaccination always reduced the total number of infections over
a period of 15 years after vaccine introduction, suggesting that vaccine is likely to
be effective. As these spikes can pose immediate problems by overburdening the resources, policy makers should consider the possibility of transient spikes and prepare
to mitigate the burden of these spikes while making vaccination program.
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Appendix A
A.1

Stability analysis

Stability analysis of the vector–host model
For the vector–host model (3.1), scaling the state variables by their respective

population sizes, to the proportions hS = HS /H, hI = HI /H, hR = HR /H, vS =
VS /V and vI = VI /V , gives the system of differential equations
dhS
dt
dhI
dt
dhR
dt
dvS
dt
dvI
dt

= µH − βaH vI hS − µH hS ,
= βaH vI hS − γH hI − µH hI ,
= γH hI − µH hR ,

(1)

= µV − βaV hI vS − µV vS ,
= βaV hI vS − µV vI .

Using the next-generation method (Diekmann et al., 2010), the basic reproductive
number is
R0 =

βaH βaV
.
µV (µH + γH )

(2)

Because hS + hI + hR = 1 and vS + vI = 1, the reduced system
dhS
= µH − βaH vI hS − µH hS ,
dt
dhI
= βaH vI hS − γH hI − µH hI ,
dt
dvI
= βaV hI vS − µV vI ,
dt

(3)

is equivalent to the full system (1). This system is defined on the domain

Ω = {(hS , hI , vI ) : 0 ≤ vI ≤ 1, 0 ≤ hS , 0 ≤ hI , hS + hI ≤ 1}.

81

(4)

A simple check shows that the vector field defined by model (3) on the boundary of Ω
does not point to the exterior of Ω, so Ω is positively invariant under the flow induced
by system (3). This guarantees that the model numbers of humans and mosquitoes in
the various epidemiological compartments never become negative, which is an obvious
biological constraint.
The equilibrium points of system (3) are

E0 = (1, 0, 0)

and

Ee = (h∗S , h∗I , vI∗ ),

(5)

where

h∗S =

δ+M
,
δ + M R0

h∗I =

R0 − 1
,
δ + M R0

vI∗ =

δ(R0 − 1)
,
(δ + M )R0

(6)

with

δ=

βaV
µV

and

M=

µH + γH
.
µH

(7)

E0 is the disease-free equilibrium and Ee is the endemic equilibrium. For R0 < 1, E0
is the only equilibrium in Ω but the endemic equilibrium Ee also lies in Ω for R0 ≥ 1.
The local stability of the equilibrium points is governed by the Jacobian matrix


0
−βaH hS 
−βaH vI − µH


.
DF = 
β
v
−(µ
+
γ
)
β
h
aH
I
H
H
aH
S




0
βaV − βaV vI −βaV hI − µV
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(8)

A.1.1

Disease-free equilibrium
The Jacobian matrix (8) at E0 is


0
−βaH 
−µH


DF (E0 ) = 
−(µH + γH ) βaH 
 0
,


0
βaV
−µV

(9)

which has eigenvalues

−µH

and

−(µH + γH + µV ) ±

p
(µH + γH + µV )2 − 4µV (µH + γH )(1 − R0 )
.
2
(10)

All of the eigenvalues have negative real part for R0 < 1 and so E0 is locally asymptotically stable for R0 < 1.
To show global stability of E0 , we consider the Lyapunov function on interior
of Ω
Λ=

βaH
vI + hI
µV

(11)

which has orbital derivative
βaH dvI dhI
dΛ
=
+
dt
µV dt
dt

(12)

= −βaH (1 − hS )vI − (µH + γH )[1 − R0 (1 − vI )]hI .
For R0 ≤ 1, the orbital derivative

dΛ
dt

≤ 0 in Ω and the subset of Ω where

dΛ
dt

= 0 is

given by
(1 − hS )vI = 0
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(13)

and
hI = 0 if R0 < 1,
(14)
hI vI = 0 if R0 = 1.
Thus {E0 } is the only invariant set contained in

dΛ
dt

= 0. Also, the interior of Ω is

bounded. Therefore, E0 is locally stable and all trajectories starting in Ω approach E0
as t → +∞ (Hale, 1969, p. 317, Corollary 1.1). This establishes the global asymptotic
stability of E0 for R0 ≤ 1.
For R0 > 1, the eigenvalue
−(µH + γH + µV ) +

p
(µH + γH + µV )2 − 4µV (µH + γH )(1 − R0 )
> 0,
2

(15)

so E0 is unstable.
A.1.2

Endemic equilibrium
As R0 increases through 1, the disease-free equilibrium E0 becomes unstable

and the endemic equilibrium Ee moves from outside to inside Ω. The Jacobian matrix
at Ee is


δ+M R0
−µH δ+M

µH M (R0 −1)
DF (Ee ) = 

δ+M

0



0

R0 δ+M
− µH M
δ
δ+M R0 

−µH M

µH M R0 δ+M
δ
δ+M R0

µV δ δ+M R0
R0 δ+M

δ+M
−µV R0 δ+M
R0


.



(16)

The characteristic polynomial of matrix (16) is

p(λ) = λ3 + Aλ2 + Bλ + C,
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(17)

where
δ + M R0
δ+M
+ µH M + µV R0
δ+M
δ + M R0
µH µV M (R0 − 1)δ
δ + M R0
+ µV µH R0 +
B = µ2H M
δ+M
δ + M R0
A = µH

(18)

C = µ2H µV M (R0 − 1).
For R0 > 1, the coefficients A, B, and C are positive and
AB > µ2H µV M R0 > C,

(19)

so the characteristic polynomial (17) satisfies the Routh–Hurwithz conditions (Brauer
and Castillo-Chávez, 2001). Therefore, Ee is locally asymptotically stable.

A.2

Comparing equilibria of the vector–host and SIR model
The endemic equilibrium (6) for the vector–host model has
h∗S

H
1 + βµaH
R0
δ+M
=
=
,
µH
δ + M R0
R0 + βaH R0

h∗I =

R0 − 1
µ
H
= (R0 − 1)
δ + M R0
(µH + γH ) R0 +

(20)
µH
R
βaH 0

.

If
µH
R0  1,
βaH

(21)

as is true of our ML estimates, then since R0 > 1,
h∗S ≈
h∗I

1
,
R0

µH
µH
≈ (R0 − 1)
= (R0 − 1) ,
(µH + γH )R0
β
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(22)

where
β=

βaV βaH
,
µV

which is exactly the endemic equilibrium of the SIR model (3.3).
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(23)

Appendix B

Steady-state solution

Rewriting the model (4.1) in proportion form by scaling the state variables by
their respective population sizes, to the proportions hS = HS /H, hI = HI /H and
hR = HR /H, gives
dhS
= µH − βhS hI − µH hS ,
dt
dhI
= βhS hI − (γH + µH )hI
dt
dhR
= γH hI − µH hR ,
dt

(24)

The endemic steady-state solution of model (24) is

h∗S =

γH + µH
,
β

h∗I =

µH (β − γH − µH )
,
β(µH + γH )

h∗R =

γH (β − γH − µH )
.
β(µH + γH )

(25)

γH (R0 − 1)
.
R0 (µH + γH )

(26)

The endemic steady-state solution can be re-written as

h∗S =

1
,
R0

h∗I =

µH (R0 − 1)
,
R0 (µH + γH )

h∗R =

where R0 = β/(γH + µH ) is the basic reproduction number.
The cumulative class hC in proportion form is
dhC
= pβhS hI ,
dt

(27)

and when system is in steady-state, the force of infection is hS = h∗S and hI = h∗I .
So, integrating (27) when system is in steady-state gives, hC (t) = pβh∗S h∗I t + C and
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by plugging t = 1 year, we get

hC (1) =

pµH (R0 − 1)
+ hC (0).
R0

(28)

and thus
R0 − 1
hC (1) − hC (0)
=
R0
pµH

(29)

Substituting (29) in the expression for h∗R in (26), we get a relation between the
population immunity and the cumulative DHF after one year:

h∗R =

(HC (1) − HC (0))γH
.
(µH + γH )pµH H

(30)

where HC (0) is cumulative DHF incidence in the beginning of epidemic and HC (0) is
cumulative DHF incidence over one year. H is total population.
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Appendix C
C.1

Dengue vaccination models

Main model
We developed a simple deterministic model for dengue to explore the short-

and long-term effects of vaccine introduction. The model consists of four unvaccinated (U ), four vaccinated (V ) and one recovered (R) compartment, the variables for
which represent the number of people in that compartment over time (Figure 5.1). An
individual with no prior dengue infection (subscript S) can have a primary infection
from any serotype of dengue (I1), recovery from which provides him with life-long
immunity to that serotype (S2). He can then acquire infection from any of the remaining three serotypes, and enter the secondary-infection class (I2). Third or fourth
infection from dengue is very rare (Halstead, 2003), so we assume that an individual
recovering from secondary infection becomes immune to all serotypes (R). Individuals in both primary- and secondary-infection class recover at rate γ = 7/365 y−1 so
that the mean infectious period is 7 days (Gubler, 1998a). The parameters B and
µ are natural birth and death rates in humans respectively, which were chosen to be
B = µ = 1/50 y−1 so that the mean human lifespan is 50 years and the population size
is constant. Dengue-induced mortality in humans is around 1–2% (Rajapakse, 2011)
and thus ignored in our model for simplicity. We were only interested in infections in
humans, so we did not model mosquito population explicitly (Pandey et al., 2013).
Infection occurs when a susceptible individual comes in contact with individuals from
any of the infectious classes through mosquito bites at the rate given by the force of
infection
λ(t) = [1 +  cos(2πt)]
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βI(t)
,
N

(31)

where the total number of people currently infected is

I(t) = UI1 (t) + UI2 (t) + VI1 (t) + VI2 (t),

(32)

N is the total human population size and β is a composite transmission parameter
(Pandey et al., 2013), taken to be β = 400 y−1 (Cummings et al., 2005). Seasonality
in the mosquito population was captured by the cosine term in the force of infection,
where t is units of years, making transmission most intense at the beginning of a year
(i.e. when t is near an integer 0, 1, 2, ...) and least intense in the middle of a year (t
near 0.5, 1.5, 2.5, ...). We used a small amplitude of seasonal forcing,  = 0.1. The
force of infection for secondary infection was reduced by the factor σ =

3
4

since they

are only susceptible to 3 of the 4 serotypes.
The vaccination program with two components was modeled: a proportion p
of newborns are vaccinated and rest of the susceptible population is vaccinated at
rate v. The vaccine of efficacy φ was modeled as reducing the force of infection by
the factor 1 − φ.
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Parameter
β

B
µ
γ
σ
p
v
φ

Definition
transmission parameter (y−1 )
seasonal-forcing amplitude
constant birth rate (y−1 )
natural mortality rate (y−1 )
recovery rate (y−1 )
susceptibility reduction for secondary infection
proportion of newborns vaccinated
vaccination rate for rest of population
vaccine efficacy

Values
400
0.1
20/1000
20/1000
365/7
3/4
(0–1)
(≥ 0)
(0–1)

Table C.1: Parameters of the dengue vaccination models.
The model equations are
dUS1
dt
dUI1
dt
dUS2
dt
dUI2
dt
dVS1
dt
dVI1
dt
dVS2
dt
dVI2
dt
dR
dt

= (1 − p)BN − (λ + v + µ)US1 ,
= λUS1 − (γ + µ)UI1 ,
= γUI1 − (σλ + v + µ)US2 ,
= σλUS2 − (γ + µ)UI2 ,
= pBN + vUS1 − [(1 − φ)λ + µ]VS1 ,

(33)

= (1 − φ)λVS1 − (γ + µ)VI1 ,
= γVI1 + vUS2 − [σ(1 − φ)λ + µ]US2 ,
= σ(1 − φ)λVS2 − (γ + µ)VI2 ,
= γ(UI2 + VI2 ) − µR.

The parameters of the model are also shown in Table C.1.
For the pre-vaccine state, using parameter values in Table C.1, setting both
vaccination rates p and v to 0, setting the initial conditions for unvaccinated susceptible individuals with no prior infection, unvaccinated infected individuals with no
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prior infection and permanently recovered individuals to be 0.09, 0.01 and 0.9, with
all other initial conditions to be zero, we simulated the dengue model (33) until it
reached a limit cycle, a regular periodic oscillation. With the parameter values used,
the model (33) converged to a 2-year cycle (Figure 5.2 and 5.3). We defined t = 0
to be just before the year with the larger peak in prevalence (e.g. see Figure 5.2(A)).
In most of the simulations, vaccination was begun at tv = 0, but we also varied the
start time tv ∈ [0, 2) (Figure 5.6).
To measure effectiveness of the vaccination program, we used 15-year maximum prevalence
max

I(t),

(34)

I(t) dt

(35)

I(t) dt,

(36)

t∈[tv ,tv +15]

15-year total infections
tv +15

Z
γ

tv

and long-term annual incidence
γ
P

Z

tc +P

tc

where tc is a time after the system has converged to the post-vaccine limit cycle and
P is the period of that limit cycle.

C.2

Simpler model
For our simpler dengue model, we assumed that there is no secondary infec-

tion so that an individual after recovering from a dengue infection is immune to all

92

serotypes. This reduces our original dengue model (33) to
dUS1
dt
dUI1
dt
dVS1
dt
dVI1
dt
dR
dt

= (1 − p)BN − (λ + v + µ)US1 ,
= λUS1 − (γ + µ)UI1 ,
= pBN + vUS1 − [(1 − φ)λ + µ]VS1 ,

(37)

= (1 − φ)λVS1 − (γ + µ)VI1 ,
= γ(UI1 + VI1 ) − µR,

with the same force of infection (31), but with total number infected

I(t) = UI1 (t) + VI1 (t).

C.3

(38)

More complex model
A more complex model compared to the model (33) was obtained by adding

the hypothesis of short-term cross-protection after primary infection. Wearing and
Rohani (2006) hypothesized that after recovering from primary infection, an individual has short-term cross-protection to the other serotypes for about 9 months, after
which he becomes susceptible to the remaining three serotypes. We added two classes
of people temporarily immune to all serotypes, one for unvaccinated (UT ) and one
for vaccinated (VT ) people, to our existing model. After primary infection, people
now enter these temporary immune classes, and before moving on to be susceptible
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to secondary infection. The model equations for this new model are
dUS1
dt
dUI1
dt
dUT
dt
dUS2
dt
dUI2
dt
dVS1
dt
dVI1
dt
dVT
dt
dVS2
dt
dVI2
dt
dR
dt
where

1
ρ

= (1 − p)BN − (λ + v + µ)US1 ,
= λUS1 − (γ + µ)UI1 ,
= γUI1 − (ρ + µ)UT ,
= ρUT − (σλ + v + µ)US2 ,
= σλUS2 − (γ + µ)UI2 ,
= pBN + vUS1 − [(1 − φ)λ + µ]VS1 ,

(39)

= (1 − φ)λVS1 − (γ + µ)VI1 ,
= γVI1 − (ρ + µ)VT ,
= ρVT + vUS2 − [σ(1 − φ)λ + µ]US2 ,
= σ(1 − φ)λVS2 − (γ + µ)VI2 ,
= γ(UI2 + VI2 ) − µR,

= 0.75 y is the average duration of short-term cross protection against all

serotypes. With the same force of infection and total number infected as before, (31)
& (32).
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